antibodydepend
cellular
cytotox
adcc
straightforward
explan
antibodi
activ
fail
complex
explan
consid
context
present
review
literatur
vitro
vivo
antivir
activ
antibodi
includ
data
earli
studi
present
day
believ
earli
studi
misinterpret
misconcept
propag
ever
sinc
vivo
convent
distinguish
phenomenolog
two
type
antibodi
antivir
activ
one
abil
antibodi
protect
infect
present
immedi
follow
infect
abil
antibodi
interfer
establish
infect
good
reason
make
distinct
strong
evid
antibodi
effect
mani
differ
virus
protect
role
ambigu
role
ongo
infect
distinct
may
origin
least
part
activ
antibodi
propag
infect
free
viru
compar
activ
propag
via
celltocel
spread
evid
number
virus
vitro
indic
lower
antibodi
concentr
requir
inhibit
infect
propag
free
viru
requir
inhibit
infect
propag
celltocel
spread
vitro
antivir
activ
separ
activ
virion
activ
infect
cell
activ
virion
often
consid
neutral
defin
loss
infect
ensu
antibodi
molecul
bind
viru
particl
usual
occur
without
involv
agenc
unusu
activ
antibodi
parallel
inhibit
toxin
enzym
dimmock
antibodydepend
complementmedi
virolysi
also
activ
direct
free
virion
antibodi
also
bind
viral
product
infect
cell
trigger
effector
function
includ
activ
complement
adcc
antibodymedi
phagocytosi
direct
free
virion
well
infect
cell
addit
bind
antibodi
infect
cell
propos
inhibit
intracellular
viral
replic
certain
case
begin
consid
vitro
antivir
activ
antibodi
neutral
virus
antibodi
extens
studi
last
centuri
mani
mechan
neutral
propos
review
burnet
et
al
daniel
dellaport
westaway
dimmock
fazeka
de
stgroth
parren
et
al
mechan
includ
aggreg
inhibit
viral
entri
inhibit
attach
inhibit
fusion
target
cell
well
post
entri
mechan
interfer
primari
secondari
uncoat
genet
inform
viru
eg
dimmock
suggest
antibodi
may
neutral
act
via
sever
mechan
simultan
sequenti
dimmock
kinet
studi
viru
neutral
interpret
indic
neutral
often
follow
singleor
fewhit
kinet
bind
singl
antibodi
trigger
event
lead
virion
inactiv
dimmock
dulbecco
et
al
mandel
mclain
dimmock
explain
singlehit
neutral
virus
case
number
antibodi
molecul
bound
viru
particl
neutral
event
eg
antibodi
molecul
per
virion
polioviru
per
virion
case
influenza
see
icenogl
et
al
taylor
et
al
antibodyinduc
conform
chang
viral
capsid
mandel
exist
antigen
ident
neutralizationrelev
neutralizationirrelev
antibodi
bind
site
virion
surfac
propos
icenogl
et
al
taylor
et
al
myriad
propos
neutral
mechan
howev
somewhat
difficult
reconcil
natur
antibodi
gener
select
antibodi
superb
bind
molecul
select
highaffin
bind
rather
abil
induc
critic
conform
chang
viral
capsid
protein
envelop
spike
review
propos
much
simplist
unifi
mechan
neutral
suggest
neutral
antibodi
gener
act
coat
surfac
pathogen
neutral
pathogen
repres
entiti
coat
reach
critic
densiti
antibodi
coat
prevent
pathogen
interact
properli
target
cell
therebi
interf
initi
product
infect
differenti
effect
antibodi
coat
distinct
virus
inhibit
attach
viral
entri
appar
post
entri
effect
may
due
epitop
recogn
also
may
part
explain
differ
viru
biolog
rather
direct
induct
specif
event
antibodi
mechan
suggest
socal
neutral
nonneutr
epitop
exist
distinct
entiti
viral
surfac
suggest
past
eg
dimmock
neutral
epitop
gener
repres
antibodyaccess
structur
virion
surfac
present
valenc
high
enough
critic
antibodi
densiti
calcul
achiev
lowdens
epitop
repres
true
nonneutr
epitop
critic
densiti
could
achiev
combin
two
antibodi
sever
distinct
lowdens
epitop
neoepitop
may
exist
transient
virion
exampl
virustarget
cell
fusion
necessarili
form
except
model
discuss
view
antibodi
epitop
neutral
neoepitop
access
antibodi
point
viru
infect
process
effect
coat
occur
neutral
antibodi
cryptic
epitop
howev
appear
rel
rare
b
antibodi
neutral
bind
viru
neutral
viru
antibodi
requir
antibodi
bind
coat
viru
therefor
antibodi
bind
virion
may
use
indic
vivo
activ
realiti
measur
antibodi
bind
virion
often
technic
demand
furthermor
mani
viru
prepar
infecti
particl
total
particl
ratio
low
introduc
element
uncertainti
regard
envelop
homogen
therefor
measur
bind
envelop
surfac
infect
cell
often
prefer
note
though
virus
express
nonstructur
modifi
viral
protein
infectedcel
surfac
virion
nonneutr
antibodi
ineffect
free
viru
may
abl
protect
viral
infect
vivo
mediat
destruct
infect
cell
discuss
detail
human
immunodefici
viru
type
good
correl
describ
neutral
bind
envelop
spike
surfac
infect
cell
parren
et
al
roben
et
al
sattentau
moor
howev
problem
aris
measur
bind
envelop
cell
surfac
import
minim
problem
much
possibl
proper
experiment
design
first
envelop
spike
shed
protein
provid
opportun
observ
antibodi
appar
bind
well
infect
cell
surfac
bind
function
envelop
spike
antibodi
transmembran
tm
unit
probabl
fall
categori
may
bind
inactiv
envelop
spike
expos
follow
shed
surfac
unit
su
second
type
artifact
provid
antibodi
bind
shed
interact
primari
receptor
antibodi
appar
bind
cell
reflect
bind
envelop
spike
signific
mani
nonneutr
epitop
access
oligomer
envelop
spike
expos
monomer
parren
et
al
third
type
artifact
may
aris
envelop
overexpress
exampl
express
recombin
envelop
glycoprotein
control
strong
promotor
thu
seem
clear
unprocess
envelop
precursor
glycoprotein
express
cell
surfac
certain
condit
eg
dubay
et
al
karlsson
et
al
sinc
mani
antibodi
bind
envelop
spike
bind
well
unprocess
opportun
erron
conclus
parren
et
al
gener
agreement
antienvelop
antibodi
bind
envelop
spike
virion
neutral
consider
less
agreement
whether
antibodi
bind
envelop
spike
neutral
viru
antibodi
bind
well
envelop
spike
neutral
viru
answer
question
number
import
ramif
mani
antibodi
bind
envelop
spike
neutral
bind
necessarili
good
indic
like
antivir
efficaci
implic
vaccin
design
antibodi
bind
also
neutral
envelop
spike
antigen
properti
ideal
vaccin
candid
hand
envelop
spike
induc
nonneutr
antibodi
may
optim
antigen
particular
induct
nonneutr
antibodi
bind
envelop
spike
inhibit
bind
neutral
antibodi
would
undesir
opinion
issu
nonneutr
bind
antibodi
present
recent
summar
argu
overwhelmingli
good
correl
neutral
virion
bind
except
experi
studi
human
monoclon
antibodi
mab
respiratori
syncyti
viru
rsv
ebola
viru
excel
correl
bind
envelop
spike
neutral
studi
measur
bind
infect
cell
gener
seen
close
correl
halfmaxim
antibodi
bind
antibodi
concentr
requir
give
neutral
suggest
neutral
directli
relat
occup
site
virion
neutral
increment
increas
antibodi
occup
irrespect
epitop
recogn
lead
increas
inhibit
infect
parren
et
al
et
al
issu
discuss
much
greater
detail
irrespect
observ
strong
tradit
virolog
bind
ie
virion
nonneutr
antibodi
earli
studi
describ
nonneutraliz
fraction
viru
persist
even
high
antibodi
concentr
addit
antiantibodi
could
reduc
infect
fraction
seem
viru
aggreg
may
partli
respons
phenomenon
walli
melnick
discuss
detail
also
note
nonneutraliz
fraction
describ
hepat
hepat
c
result
viru
associ
lipid
lipoprotein
lemon
binn
princ
descript
bind
nonneutr
antibodi
aros
failur
appreci
antibodi
bind
isol
envelop
molecul
necessarili
often
bind
envelop
spike
classic
exampl
mani
antibodi
describ
bind
high
affin
monomer
unprocess
howev
show
substanti
affin
envelop
spike
review
parren
et
al
antibodymedi
enhanc
infect
phenomenon
may
support
exist
nonneutr
bind
antibodi
sinc
antibodi
parren
burton
involv
must
bind
virion
howev
key
observ
enhanc
describ
appear
occur
neutral
antibodi
subneutr
concentr
eg
halstead
moren
et
al
favor
view
antibodi
enhanc
effect
aris
condit
lowlevel
antibodi
coat
virion
rather
indic
antibodi
abil
bind
well
virion
neutral
discuss
detail
phenomenon
suggest
howev
potenti
problem
vaccin
induc
low
level
neutral
antibodi
clear
exampl
good
evid
antibodi
bind
well
virion
envelop
spike
without
effect
neutral
concentr
would
expect
complet
coat
virion
provid
studi
rabi
viru
discuss
later
flamand
et
al
howev
appear
rabi
mutant
viru
rather
antibodi
unusu
properti
end
nineteeth
centuri
willem
beijerinck
made
import
concept
advanc
recognit
virus
term
contagium
vivum
fluidum
repres
infecti
entiti
distinct
bacteria
beijerinck
van
kammen
great
advanc
understand
inactiv
virus
antibodi
made
earli
twentieth
centuri
promin
articl
burnet
colleagu
review
stateoftheart
antibodi
neutral
burnet
et
al
argu
neutral
studi
bacteriophag
plant
anim
virus
show
gener
neutral
revers
ii
one
antibodi
requir
neutral
base
studi
number
anim
virus
includ
vaccinia
influenza
summar
viru
antibodi
combin
revers
infect
otherwis
given
viru
particl
determin
amount
antibodi
unit
time
effect
contact
suscept
cell
revers
indic
union
antibodi
intrins
inactiv
effect
viru
conclus
neutral
revers
requir
bind
multipl
antibodi
molecul
virion
sinc
disput
rediscov
mani
later
public
particular
observ
singlehit
kinet
number
experiment
system
interpret
evid
neutral
bind
singl
antibodi
critic
site
virion
jern
avegno
show
inactiv
bacteriophag
follow
firstord
kinet
inactiv
may
result
singl
event
plausibl
neutral
antibodi
bind
tailplat
phage
essenti
compon
infect
process
width
tailplat
similar
length
antibodi
molecul
jern
avegno
influenti
studi
sharpli
contradict
conclus
burnet
et
al
publish
dulbecco
colleagu
also
analyz
neutral
western
equin
enceph
viru
wee
polioviru
specif
antisera
dulbecco
et
al
found
curv
describ
logarithm
viru
surviv
function
time
gener
display
initi
shoulder
lag
time
interpret
neutral
follow
firstord
kinet
initi
time
period
howev
slope
curv
decreas
eventu
becom
horizont
indic
exist
persist
appar
neutralizationresist
fraction
viru
dissoci
poliovirusantibodi
complex
could
observ
slight
dissoci
weeantibodi
complex
conclud
attach
singl
neutral
antibodi
molecul
critic
site
suffici
inactiv
viru
particl
neutral
irrevers
dulbecco
et
al
howev
result
manuscript
dulbecco
et
al
could
explain
neutral
model
develop
first
clear
lag
time
wee
neutral
observ
kinet
neutral
experi
perform
temperatur
lower
c
even
c
dulbecco
et
al
note
small
lag
time
may
exist
although
experiment
condit
use
may
made
detect
difficult
furthermor
multipl
curv
describ
logarithm
viru
surviv
function
increas
antibodi
concentr
follow
theoret
curv
base
model
experiment
curv
bent
upward
high
antibodi
concentr
rather
downward
deviat
could
complet
explain
persist
viru
fraction
author
conclud
differ
fraction
may
present
challeng
stock
consist
virion
differ
number
critic
site
unequ
distribut
critic
site
dulbecco
et
al
krummel
uhr
recogn
critic
site
neutral
model
develop
often
fit
data
later
time
point
cours
neutral
kinet
experi
argu
highli
symmetr
viru
surfac
array
repeat
coatprotein
subunit
bacteriophag
studi
like
multipl
antibodi
molecul
requir
neutral
kinet
neutral
experi
residu
infect
assess
use
two
differ
method
inde
indic
bacteriophag
cover
antibodi
may
retain
infect
significantli
observ
appar
faster
neutral
rate
residu
infect
assess
use
decis
tube
method
rather
convent
direct
plate
method
kinet
neutral
experi
antibodi
phage
mix
sampl
drawn
multipl
time
point
incub
bacteria
plate
assess
residu
infect
decis
tube
method
excess
addit
neutral
antiserum
ad
short
time
ad
reaction
sampl
bacteria
wherea
infecti
titer
determin
method
similar
prior
addit
neutral
antibodi
decis
tube
method
measur
markedli
decreas
infecti
titer
compar
parren
burton
convent
plate
method
time
point
addit
antibodi
neutral
phage
effect
irrevers
condit
use
differ
observ
could
explain
prevent
reactiv
neutral
phage
eg
dissoci
antibodyviru
complex
plausibl
explan
phage
partial
coat
antibodi
molecul
neutral
phage
infect
bacteria
slower
rate
nake
phage
similar
delay
initi
bacteriophageinduc
lysi
neutral
experi
previous
interpret
indic
partial
antibodyco
infecti
phage
particl
exist
review
burnet
et
al
enter
infect
function
phageantibodi
complex
mathemat
model
develop
krummel
uhr
model
better
match
data
clearli
indic
observ
reaction
rate
neutral
antibodi
bacteriophag
first
order
even
condit
antibodi
excess
krummel
uhr
sever
mechan
describ
neutral
picornavirus
includ
aggreg
virion
stabil
inhibit
viru
attach
induct
conform
chang
viral
capsid
see
smith
recent
review
induct
conform
chang
result
larg
chang
isoelectr
point
upon
antibodi
bind
promin
prompt
detail
investig
studi
carri
polioviru
human
rhinoviru
hrv
neutral
polioviru
studi
extens
dulbecco
et
al
argu
neutral
polioviru
irrevers
follow
firstord
kinet
discuss
studi
perform
mandel
confirm
reactiv
viru
infect
dilut
antibodyviru
complex
could
demonstr
measur
taken
sever
month
appar
irrevers
reaction
appear
due
howev
tight
bind
antibodi
polioviru
rather
induct
perman
chang
viral
particl
demonstr
neutral
rabbit
antibodi
could
elut
poliovirion
low
ph
accompani
quantit
reactiv
viru
activ
mandel
mandel
found
capsid
protein
polioviru
may
exist
two
conform
state
character
distinct
isoelectr
point
state
isoelectr
point
state
b
isoelectr
point
neutral
antibodi
found
stabil
virion
state
b
mandel
propos
bind
neutral
antibodi
lock
viral
capsid
noninfecti
conform
render
resist
uncoat
follow
adsorpt
target
cell
singlehit
kinet
polioviru
neutral
could
explain
induct
gener
molecular
rearrang
viral
capsid
bind
singl
antibodi
critic
site
capsid
molecul
mechan
feasibl
polioviru
capsid
close
pack
structur
make
conform
cooper
among
capsid
subunit
possibl
mandel
howev
relationship
conform
state
infect
complet
infecti
viru
b
state
could
detect
particularli
low
antibodi
multipl
even
subtract
infect
assign
small
fraction
viru
natur
occur
b
state
mandel
correl
bind
neutral
antibodi
polioviru
shift
isoelectr
point
gener
held
studi
monoclon
antibodi
emini
et
al
although
except
note
brioen
et
al
emini
et
al
chang
isoelectr
point
follow
bind
neutral
antibodi
also
describ
anoth
picornaviru
name
hrv
colonno
et
al
howev
case
particularli
clear
induc
conform
chang
play
major
role
picornaviru
neutral
review
hewat
blaa
smith
convinc
data
come
cryoelectron
microscopi
cryoem
xray
crystallographi
virusantibodi
complex
show
rhinoviru
neutral
without
induct
larg
conform
chang
virion
capsid
hewat
blaa
smith
smith
et
al
smith
et
al
furthermor
chang
isoelectr
point
observ
follow
bind
larg
number
differ
antibodi
rang
epitop
rhinoviru
appear
unlik
antibodi
would
induc
common
conform
chang
requir
neutral
like
hypothesi
chang
isoelectr
point
result
chang
occur
expos
highli
flexibl
portion
capsid
protein
rather
structur
rearrang
viral
capsid
che
et
al
smith
although
result
bind
neutral
antibodi
chang
probabl
mostli
irrelev
mechan
neutral
antibodi
activ
like
affect
hrv
infect
appear
inhibit
viru
attach
strongli
neutral
mab
bind
epitop
locat
loop
b
c
strand
capsid
protein
situat
close
canyon
harbor
bind
site
cellular
hrv
receptor
review
smith
mab
neutral
inhibit
attach
demonstr
attach
antibodi
molecul
per
hrv
particl
requir
reduc
attach
smith
et
al
significantli
colonno
et
al
shown
fab
fragment
antibodi
four
neutral
epitop
hrv
inhibit
attach
locat
moredist
hrv
receptor
bind
site
linear
correl
found
inhibit
attach
plot
function
antibodi
concentr
furthermor
rank
order
neutral
potenc
follow
rank
order
inhibit
attach
studi
hrv
clearli
demonstr
bind
one
antibodi
molecul
requir
neutral
suggest
role
parren
burton
antibodi
occup
bind
site
viru
discuss
follow
section
studi
neutral
polioviru
suggest
neutral
picornaviru
also
requir
attach
multipl
antibodi
molecul
particular
insight
relationship
antibodi
bound
polioviru
neutral
provid
philipson
colleagu
develop
aqueou
polym
phase
system
studi
interact
neutral
antibodi
polioviru
found
virion
complex
antibodi
could
separ
free
virion
ad
polym
mixtur
follow
simpl
phasesepar
techniqu
phase
system
sensit
detect
antibodi
bind
virion
compar
convent
neutral
test
clearli
indic
neutral
antibodi
bound
virion
neutral
could
detect
interestingli
bind
titer
phase
system
method
time
greater
serum
neutral
titer
polioviru
signific
number
becom
clear
shortli
addit
studi
philipson
interact
antibodi
polioviru
use
countercurr
distribut
furthermor
show
low
antibodi
input
virionantibodi
complex
separ
free
viru
retain
infect
philipson
neutral
antibodi
dose
defin
antibodi
concentr
viru
infect
reduc
infect
nonneutr
viru
stock
icenogl
et
al
determin
neutral
dose
polioviru
studi
use
radiolabel
viru
antibodi
demonstr
bind
averag
antibodi
molecul
polioviru
particl
result
neutral
two
neutral
model
propos
explain
result
context
firstord
kinet
critic
site
hypothesi
bind
one
four
site
viru
lead
neutral
stepwis
model
bind
site
reduc
infect
model
howev
conflict
studi
philipson
et
al
discuss
demonstr
antibodi
bind
virion
detect
prior
neutral
significantli
observ
occup
antibodi
molecul
per
virion
requir
neutral
consist
observ
differ
bind
neutral
titer
philipson
studi
straightforward
conclus
singlehit
hypothesi
polioviru
neutral
correct
mechan
neutral
polioviru
similar
hrv
overal
architectur
polioviru
hrv
similar
virus
similar
proport
consist
capsid
surround
positivestrand
rna
genom
threedimension
structur
polioviru
complex
solubl
form
receptor
recent
solv
belnap
et
al
et
al
polioviru
receptor
footprint
similar
observ
rhinoviru
receptor
bound
immunolog
hrv
bind
canyon
narrow
surfac
depress
viral
surfac
may
therefor
complet
surpris
stoichiometr
analys
discuss
yield
similar
result
hrv
polioviru
data
suggest
attach
antibodi
molecul
requir
neutral
picornavirus
poliovirushrv
dimens
studi
horaud
colleagu
blondel
et
al
crainic
et
al
diamond
et
al
suggest
antibodi
may
bind
polioviru
without
neutral
conclus
made
basi
studi
use
neutral
antibodi
analyz
activ
neutral
bind
rang
antigen
polioviru
variant
distinct
serotyp
escap
mutant
exampl
serotyp
appear
bound
antibodi
immunoprecipit
assay
neutral
studi
howev
made
distinct
strong
weak
bind
mutat
polioviru
envelop
near
antibodi
bind
site
may
result
decreas
antibodi
affin
polioviru
mutant
question
result
level
occup
low
neutral
viru
exampl
shown
studi
discuss
interpret
support
observ
addit
antiantibodi
studi
result
neutral
mutant
virus
blondel
et
al
presum
antiantibodi
effect
increas
affin
avid
rais
occup
level
requir
neutral
see
singlehit
model
base
observ
infect
start
decreas
immedi
follow
addit
antibodi
viru
absenc
detect
lag
phase
ie
period
infect
remain
unaffect
follow
antibodi
addit
often
taken
support
evid
singlehit
model
dulbecco
et
al
icenogl
et
al
mandel
mclain
dimmock
taylor
et
al
may
argu
howev
reaction
antibodi
nanomolar
affin
cognat
antigen
occur
rapidli
eg
scicluna
mccullough
sampl
drawn
kinet
studi
interv
minut
greater
may
possibl
measur
surviv
viru
fraction
fast
enough
observ
presenc
absenc
lag
phase
standard
condit
dellaport
westaway
furthermor
lag
time
neutral
kinet
inde
observ
studi
virus
experi
perform
lower
incub
temperatur
dilut
antibodi
concentr
antibodi
lower
affin
burnet
et
al
dulbecco
et
al
lafferti
philipson
taylor
et
al
difficult
reconcil
singlehit
model
requir
assumpt
mechan
parren
burton
neutral
chang
temperatur
antibodi
concentr
affin
vari
klass
moor
refer
therein
argu
firstord
neutral
reaction
give
direct
proof
neutral
singlehit
kinet
one
antibodi
molecul
neutral
one
virion
impli
firstord
kinet
revers
true
stoichiometr
analys
see
suggest
bind
one
antibodi
molecul
viru
particl
usual
requir
neutral
altern
explan
absenc
lag
phase
one
discuss
least
envelop
virus
may
found
heterogen
spike
densiti
viru
stock
virion
may
exist
low
number
activ
spike
may
requir
one
hit
neutral
klass
moor
exampl
hypothesi
may
applic
shed
virion
result
format
inact
spike
plethora
evid
indic
viru
neutral
gener
result
attach
number
antibodi
molecul
infect
particl
mani
argument
cogent
review
dellaporta
westaway
summari
argument
supplement
evid
multihit
neutral
recent
studi
present
argument
includ
r
occurr
persist
fraction
infecti
viru
r
neutral
infecti
virusantibodi
complex
sensit
viru
addit
antiantibodi
r
neutral
sensit
viru
addit
complement
r
retard
infect
sensit
viru
r
phenomenon
antibodymedi
enhanc
infect
r
addit
synergist
effect
antibodi
neutral
presenc
persist
fraction
nonneutraliz
viru
viru
prepar
sourc
much
debat
nonneutraliz
viru
fraction
attribut
presenc
lowaffin
antibodi
antibodi
prepar
particularli
earli
immun
sera
viru
heterogen
neutralizationinterfer
nonneutr
antibodi
viru
associ
lipid
lipoprotein
viru
aggreg
studi
shown
infecti
titer
persist
fraction
reduc
addit
antiantibodi
impli
fraction
contain
viru
particl
level
antibodi
coat
earli
explan
nonneutraliz
viru
fraction
attribut
phenomenon
associationdissoci
equilibria
viru
antibodi
burnet
et
al
inde
dissoci
may
play
role
lowaffin
antibodi
prepar
use
dissoci
virusantibodi
complex
occur
addit
complex
target
cell
jern
avegno
lafferti
highaffin
antibodi
prepar
howev
seem
import
factor
dulbecco
et
al
also
suggest
lowaffin
antibodi
nonneutr
antibodi
may
bind
virion
prevent
bind
neutral
antibodi
give
rise
nonneutraliz
fraction
case
howev
fraction
easili
explain
term
heterogen
viru
prepar
vaccinia
viru
rabbitpox
viru
prepar
exampl
contain
small
fraction
extracellular
envelop
viru
eev
excess
intracellular
matur
viru
imv
eev
contain
addit
wrap
membran
rel
resist
neutral
ichihashi
vanderplasschen
et
al
wrap
membran
howev
easili
damag
manipul
therebi
expos
moreneutr
sensit
imv
particl
ichihashi
vanderplasschen
et
al
mechan
rather
dissoci
lowaffin
nonneutr
antibodi
may
explain
experi
show
persist
fraction
rabbitpox
viru
neutral
follow
dilut
wash
lafferti
studi
neutral
antibodi
mous
mammari
tumor
viru
mmtv
suggest
nonneutr
mab
mmtv
could
interfer
bind
neutral
activ
neutral
mab
massey
schochetman
would
one
exampl
activ
monoclon
antibodi
inhibit
describ
howev
extrem
weak
appar
high
nonneutr
mab
neutral
mab
ratio
closer
examin
observ
block
furthermor
well
within
rang
experiment
error
mmtv
pseudotyp
neutral
assay
use
massey
schochetman
therefor
unlik
signific
aggreg
viru
may
respons
mani
observ
nonneutraliz
viru
fraction
aggreg
viru
particl
alreadi
present
prepar
form
aggreg
antibodi
may
inhibit
access
antibodi
viru
particl
insid
small
aggreg
protect
neutral
filtrat
remov
aggreg
treatment
antiantibodi
coat
aggreg
extens
inde
remov
persist
fraction
instanc
melnick
neutral
sensit
viru
antiantibodi
complement
compon
cite
argument
singlehit
kinet
indic
infecti
virusantibodi
complex
exist
dellaport
westaway
burnet
et
al
note
review
infecti
antibodybacteriophag
complex
exist
evidenc
observ
literatur
plaqu
size
reduc
presenc
antibodi
presum
occur
delay
infect
phage
low
level
antibodi
attach
krummel
uhr
demonstr
reduc
infect
rate
bacteriophag
complex
neutral
antibodi
kinet
neutral
experi
see
westaway
note
rate
penetr
west
nile
viru
preincub
neutral
antibodi
delay
viru
suscept
postattach
neutral
longer
period
time
adsorpt
target
cell
nonsensit
viru
experi
indic
antibodi
may
combin
viru
occup
low
neutral
viru
high
enough
decreas
rate
entri
target
cell
antibodymedi
enhanc
infect
phenomenon
appear
occur
neutral
antibodi
subneutr
concentr
halstead
hawk
lafferti
moren
et
al
enhanc
sensit
target
cell
depend
type
express
level
fc
andor
complement
receptor
target
cell
surfac
classic
exampl
enhanc
dengu
viru
infect
depend
interact
virionbound
antibodi
fc
receptor
express
target
cell
typic
assay
neutral
observ
rel
high
concentr
wherea
enhanc
observ
lower
concentr
use
neutral
antibodi
dengu
viru
moren
et
al
inde
show
mab
concentr
maxim
enhanc
predict
neutral
titer
hawk
lafferti
note
balanc
enhanc
neutral
depend
incub
time
viru
antibodi
observ
shift
dose
respons
curv
time
progress
enhanc
well
neutral
occur
increasingli
lower
concentr
presum
earli
time
point
attach
small
number
antibodi
lead
enhanc
reaction
progress
antibodi
attach
eventu
lead
neutral
virion
clearli
indic
enhanc
neutral
two
differ
biolog
outcom
interact
antibodi
viru
differ
level
occup
fc
receptormedi
complementmedi
antibodydepend
enhanc
infect
describ
homsi
et
al
lund
et
al
mascola
et
al
robinson
et
al
schutten
et
al
takeda
et
al
fc
receptormedi
enhanc
fc
receptormedi
endocytosi
virionantibodi
complex
may
lead
intern
viru
infect
plausibl
altern
bind
fc
receptor
antivir
activ
antibodi
stabil
interact
virion
targetcel
permit
interact
envelop
spike
viru
receptor
low
antibodi
coat
virion
connor
et
al
higher
coat
interact
may
inhibit
complement
receptor
may
mediat
enhanc
infect
via
sever
propos
mechan
either
act
receptor
opson
antibodi
complement
increas
viru
bind
cell
due
interact
opson
viru
boyer
et
al
lund
et
al
addit
virionbound
may
directli
interact
receptor
host
cell
lead
enhanc
infect
prohaszka
et
al
case
enhanc
requir
fc
part
antibodi
molecul
sullivan
et
al
suggest
lowlevel
coat
may
trigger
conform
chang
envelop
exampl
favor
fusion
virion
target
cell
coat
may
nonspecif
reduc
repuls
virion
target
cell
surfac
similar
mechan
antibodymedi
enhanc
infect
describ
sindbi
viru
flynn
et
al
phenomenon
enhanc
indic
antibodi
bind
virion
subneutr
concentr
therefor
strong
argument
import
antibodi
occup
viru
neutral
neutral
follow
multihit
kinet
high
level
occup
lead
neutral
wherea
presenc
permiss
target
cell
low
level
occup
may
lead
enhanc
infect
presenc
addit
synergist
effect
neutral
indic
role
antibodi
occup
neutral
virus
provid
argument
multihit
neutral
phenotyp
mix
experi
particular
inform
respect
shown
cell
dualli
infect
certain
virus
may
yield
phenotyp
mix
virion
rel
poorli
neutral
singl
specif
antisera
parent
virus
effect
neutral
mix
neutral
antisera
cell
dualli
infect
myxoviru
fowl
plaqu
viru
fpv
rhabdoviru
vesicular
stomat
viru
vsv
produc
viru
progeni
compos
viru
particl
mix
envelop
neutral
virion
carri
mix
envelop
poor
nonexist
neutral
assay
antivsv
antifpv
alon
howev
strong
neutral
occur
assay
carri
mixtur
two
sera
zavada
rosenbergova
similar
observ
made
phenotyp
mix
virion
vsv
sendai
viru
kimura
vsv
measl
viru
wild
et
al
wild
et
al
addit
effect
also
observ
antibodi
bind
paramyxoviru
newcastl
diseas
viru
ndv
bind
singl
mab
ndv
parren
burton
hemagglutininneuraminidas
hn
glycoprotein
leav
larg
persist
fraction
nonneutr
viru
iorio
bratt
persist
fraction
appear
bound
neutral
mab
almost
complet
neutral
addit
antiantibodi
iorio
bratt
seem
contain
larg
aggreg
viru
genotyp
distinct
virus
iorio
bratt
interestingli
persist
fraction
could
neutral
antibodi
sever
epitop
hn
glycoprotein
combin
addit
level
neutral
compar
polyclon
immun
serum
could
obtain
combin
antibodi
four
distinct
epitop
ndv
bratt
observ
consist
heterogen
ndv
hn
glycoprotein
may
exist
differ
conform
virion
surfac
neutral
la
cross
viru
level
polyclon
antibodi
could
similarli
obtain
combin
two
monoclon
antibodi
glycoprotein
kingsford
studi
suggest
role
antibodi
occup
viral
surfac
bind
site
neutral
ndv
la
cross
viru
interest
coat
virion
earli
compon
complement
system
may
enhanc
neutral
without
induc
virolysi
discuss
review
oldston
shown
infect
plasma
virion
may
reduc
vivo
deposit
virion
surfac
sullivan
et
al
presum
complement
coat
interfer
viru
interact
target
cell
therebi
contribut
neutral
adenoviru
icosahedr
capsid
characterist
long
thin
fiber
protrud
vertic
knob
end
fiber
serv
primari
receptor
attach
site
penton
base
protein
locat
base
fiber
bind
integrin
via
rgd
motif
review
unusu
observ
antibodi
direct
rgd
motif
neutral
adenoviru
infect
fab
fragment
whole
igg
molecul
cryoem
adenoviru
complex
fab
indic
fab
may
occupi
five
rgd
epitop
penton
base
complex
whole
igg
molecul
shown
bind
solubl
penton
base
stoichiometri
indic
per
penton
base
two
igg
molecul
may
bind
bival
one
monoval
intact
viru
particl
howev
central
fiber
presum
provid
sourc
steric
hindranc
prevent
igg
molecul
fab
fragment
bind
five
site
penton
base
neutral
adenoviru
immunolog
textur
antivir
activ
antibodi
antibodi
penton
base
protein
therefor
requir
occup
five
integrin
bind
site
number
eleg
detail
studi
carri
flamand
colleagu
antibodi
neutral
rabi
viru
studi
support
gener
notion
neutral
result
coat
virion
antibodi
molecul
flamand
et
al
raux
et
al
number
antibodi
molecul
bound
per
rabi
viru
particl
determin
care
correl
magnitud
neutral
achiev
found
infect
complet
preserv
fewer
igg
igm
molecul
bound
per
virion
flamand
et
al
neutral
dose
dose
infect
decreas
igg
igm
molecul
bound
per
virion
depend
antibodi
test
mark
threshold
effect
twoto
threefold
increas
number
antibodi
molecul
close
threshold
lead
drop
infecti
titer
log
flamand
et
al
three
mab
identifi
bound
viru
without
neutral
two
subsequ
shown
bind
minor
popul
envelop
spike
alter
acid
conform
envelop
raux
et
al
coat
virion
via
alter
spike
incomplet
permit
neutral
virion
maintain
lower
ph
convert
spike
acid
form
antibodi
bound
viru
neutral
one
mab
effect
neutral
wildtyp
viru
appear
satur
envelop
spike
neutral
escap
variant
molecul
igg
per
virion
neutral
antibodyco
viru
still
abl
attach
target
cell
author
consid
unlik
attach
occur
envelop
thick
antibodi
shell
coat
viru
flamand
et
al
case
appear
constitut
bona
fide
exampl
virion
coat
antibodi
without
neutral
although
rabi
mutant
viru
rather
antibodi
seem
except
rule
would
interest
elucid
mutant
viru
escap
neutral
complet
coat
antibodi
overal
studi
flamand
et
al
strongli
suggest
correl
antibodi
occup
neutral
rabi
viru
experi
show
neutral
occur
mean
critic
coat
densiti
igg
igm
molecul
bound
per
virion
investig
rel
import
bind
site
occup
epitop
specif
antibodi
neutral
use
extens
panel
neutral
mab
parren
et
al
neutral
studi
parren
burton
use
tcell
line
adapt
tcla
isol
strategi
adopt
compar
bind
number
antibodi
differ
epitop
present
form
function
oligomer
infect
cell
capac
neutral
correspond
viru
concentr
mab
yield
halfmaxim
bind
k
neutral
titer
id
similar
magnitud
would
consist
antibodi
occup
virion
bind
site
play
major
role
neutral
similar
k
id
ratio
differ
epitop
would
suggest
neutral
independ
epitop
recogn
inde
excel
correl
r
p
neutral
id
bind
oligomer
k
observ
furthermor
k
id
ratio
fell
gener
within
rel
narrow
rang
antibodi
differ
neutral
epitop
suggest
occup
bind
site
virion
major
factor
determin
neutral
irrespect
epitop
recogn
parren
et
al
illustr
fig
k
id
ratio
panel
mab
five
distinct
neutral
epitop
tcla
isol
plot
propos
model
neutral
effect
coat
virion
antibodi
attach
viru
target
cell
occur
infect
initi
presum
multipl
contact
local
area
primari
receptor
must
establish
coat
viru
critic
densiti
would
interrupt
process
fig
neutral
determin
antibodi
occup
irrespect
epitop
recogn
antibodi
concentr
yield
halfmaxim
bind
k
neutral
titer
id
k
id
ratio
determin
number
neutral
mab
bind
site
epitop
loop
loop
epitop
bind
neutral
assay
lai
mn
parren
et
al
similar
k
id
ratio
differ
epitop
suggest
neutral
independ
epitop
recogn
suggest
occup
bind
site
rather
epitop
recogn
major
determin
factor
neutral
parren
et
al
review
parren
et
al
et
al
analyz
stoichiometri
neutral
eleg
studi
use
virion
carri
mix
envelop
spike
surfac
cell
transfect
clone
potent
neutral
mab
loop
mutant
clone
resist
neutral
antibodi
lossofbind
mutat
proport
antigen
bind
site
virion
could
titrat
transfect
plasmid
encod
two
clone
differ
ratio
neutral
mix
envelop
virion
perform
high
concentr
neutral
antibodi
id
neutralizationsensit
clone
avail
bind
site
would
occupi
neutral
virion
aggreg
appear
play
signific
role
inactiv
experi
show
number
bind
site
therefor
number
bound
antibodi
molecul
increas
virus
becom
suscept
neutral
neutral
virion
occur
level
occup
level
consist
stoichiometr
argument
present
see
fig
increas
neutral
increment
indic
multihit
rather
singlehit
model
et
al
shown
averag
freshli
bud
virion
carri
approxim
envelop
spike
molecul
surfac
gelderblom
analys
predict
attach
approxim
igg
molecul
requir
neutral
virion
would
equival
one
igg
moleculespik
klass
moor
develop
quantit
model
neutral
explain
larg
differ
neutral
sensit
tcla
strain
primari
isol
see
review
neutral
model
predict
neutral
due
reduct
number
activ
envelop
spike
minimum
requir
induct
product
infect
factor
contribut
differ
neutral
sensit
differ
virusantibodi
combin
bind
constant
neutral
antibodi
envelop
spike
number
spike
surfac
minimum
number
spike
requir
attach
fusion
klass
moor
possibl
differ
spike
densiti
neutralizationsensit
tcla
strain
low
activ
spike
densiti
neutralizationresist
primari
isol
high
activ
spike
densiti
quot
import
factor
neutral
resist
klass
moor
differ
spike
densiti
tcla
strain
primari
isol
howev
controversi
karlsson
et
al
sullivan
et
al
altern
resist
may
due
poor
access
epitop
primari
isol
envelop
spike
method
determin
amount
antibodi
bound
use
purifi
radiolabel
virionantibodi
complex
eg
taylor
et
al
quantit
sodium
dodecyl
sulfatepolycrylamid
gel
electrophoresi
sdspage
eg
flamand
et
al
exampl
may
give
reliabl
data
method
stoichiometri
extrapol
kinet
analysi
may
inaccur
uncertainti
respect
mathemat
model
use
particularli
earli
studi
rappaport
determin
averag
four
antibodi
molecul
bound
per
neutral
bacteriophag
repres
neutral
dose
studi
collono
smith
colleagu
indic
hrv
neutral
inhibit
attach
bind
antibodi
molecul
per
hrv
virion
requir
reduc
hrv
attach
colonno
et
al
smith
et
al
icenogl
et
al
determin
neutral
polioviru
requir
attach
antibodi
molecul
discuss
picornavirus
polioviru
hrv
therefor
requir
attach
averag
antibodi
molecul
neutral
studi
assess
number
igg
molecul
necessari
neutral
influenza
viru
show
two
differ
mab
approxim
molecul
requir
taylor
et
al
studi
flamand
colleagu
rabi
viru
shown
averag
occup
igg
molecul
per
virion
necessari
neutral
see
flamand
et
al
raux
et
al
studi
bovin
papillomaviru
bpv
determin
number
antibodi
molecul
requir
neutral
approxim
molecul
four
mab
studi
respect
roden
et
al
averag
bound
igg
molecul
therefor
requir
neutral
bpv
virion
complex
mab
major
capsid
bpv
protein
analyz
cryoem
shown
mab
appar
requir
slightli
lower
occup
neutral
bind
hexaval
capsom
wherea
mab
also
bind
pentamer
capsom
booy
et
al
mab
bind
monoval
tip
capsom
highli
contort
project
fc
domain
angl
space
capsom
free
fab
domain
project
outward
mab
provid
dens
extend
antibodi
coat
consist
abil
inhibit
attach
bpv
target
cell
mab
bind
deepli
hexaval
capsom
adopt
immunolog
textur
antivir
activ
antibodi
linear
conform
mab
inhibit
virion
attach
effici
like
interfer
postattach
step
booy
et
al
possibl
mab
may
coat
viru
extens
lower
molecular
profil
may
therefor
effect
somewhat
lower
level
occup
rel
low
number
antibodi
requir
neutral
virus
compar
other
gener
much
discuss
critic
site
hypothes
wide
use
explain
neutral
howev
critic
neutralizationrelev
spike
differ
neutralizationirrelev
spike
defin
although
molecular
rearrang
capsid
nonenvelop
virus
may
provid
possibl
mechan
unclear
signal
would
transmit
loos
attach
spike
membran
envelop
viru
studi
suggest
bind
neutral
antibodi
exampl
hemagglutinin
ha
influenza
viru
transmit
signal
across
envelop
effect
neutral
posse
et
al
taylor
et
al
molecular
mechan
unknown
much
simpler
hypothesi
favor
us
neutral
antibodi
gener
act
coat
viru
surfac
therebi
interf
critic
step
infecti
pathway
obstruct
interact
cell
surfac
receptor
interf
molecular
rearrang
requir
viruscel
fusion
figur
provid
schemat
represent
size
virus
discuss
rel
antibodi
averag
number
antibodi
molecul
requir
neutral
virus
depict
increas
size
left
right
plot
number
antibodi
requir
neutral
function
averag
surfac
area
virus
shown
fig
straight
line
demonstr
roughli
equival
fraction
virion
surfac
independ
size
virion
must
bound
antibodi
neutral
occur
calcul
averag
surfac
area
virion
associ
antibodi
molecul
neutral
determin
slope
line
fig
line
fig
describ
formula
n
n
number
igg
molecul
requir
neutral
total
virion
surfac
area
follow
antibodi
molecul
associ
averag
nm
virion
surfac
area
neutral
unreason
assum
antibodi
molecul
provid
steric
hindranc
area
size
area
cover
circl
radiu
nm
length
antibodi
molecul
nm
approxim
nm
provid
fc
tail
high
degre
translat
rotat
flexibl
rel
fab
domain
indic
unlik
antibodi
even
bound
bival
wherebi
movement
fab
domain
restrict
could
hinder
interact
virion
surfac
protein
critic
site
target
cell
area
surround
bind
site
altern
immunolog
textur
fig
schemat
represent
virion
size
rel
antibodi
electron
microscop
imag
virus
consid
depict
scale
rel
size
antibodi
molecul
virus
larger
averag
virion
size
appear
requir
attach
antibodi
molecul
neutral
clearli
howev
virus
gener
neutral
well
avail
mab
bind
site
occupi
satur
bind
site
exampl
occur
igg
molecul
bound
per
polioviru
igg
molecul
bound
per
rabi
viru
particl
flamand
et
al
icenogl
et
al
electron
microscop
imag
provid
dr
hinder
format
intermedi
viral
entri
process
fusion
complex
believ
avail
data
agreement
occup
model
indic
antibodycov
virion
either
neutral
convinc
evid
intermedi
state
virion
cover
antibodi
low
occup
may
infect
target
cell
slowli
discuss
particl
howev
still
infecti
therefor
repres
neutral
intermedi
view
antibodi
coat
proce
beyond
critic
densiti
appear
equal
rel
constant
number
antibodi
molecul
per
unit
virion
surfac
area
virion
render
noninfecti
neutral
expect
revers
dissoci
antibodyvirion
complex
case
neutral
viru
popul
thu
understood
similar
term
partial
neutral
homogen
viru
stock
certain
concentr
antibodi
eg
simpli
repres
poisson
distribut
antibodi
molecul
attach
virion
given
point
time
fraction
virus
coat
antibodi
molecul
neutral
threshold
fulli
infecti
wherea
complementari
fraction
fulli
neutral
antibodi
typic
vast
molar
excess
viru
neutral
reaction
averag
number
bind
site
occupi
given
antibodi
concentr
thu
fraction
neutral
viru
predict
primarili
determin
antibodi
affin
virion
immunolog
antibodi
occup
neutral
intracellular
bacterium
chlamydia
trachomati
determin
studi
much
less
quantit
studi
virus
discuss
includ
discuss
studi
awar
provid
estim
number
antibodi
molecul
requir
neutral
nonvir
pathogen
studi
found
approxim
antibodi
molecul
strongli
neutral
mab
requir
reduc
infect
infecti
elementari
bodi
peel
brunham
higher
number
given
weakli
neutral
antibodi
consid
less
reliabl
sinc
studi
assum
antibodi
equilibrium
mixtur
bound
bacteria
interestingli
c
trachomati
data
fit
extrapol
line
describ
virus
fig
fig
occup
model
suggest
one
mechan
viru
could
seek
escap
neutral
antibodi
would
decreas
number
neutral
epitop
viral
surfac
mechan
inde
describ
human
cytomegaloviru
hcmv
neutral
escap
mutant
isol
patient
treat
neutral
human
antibodi
hcmv
surfac
glycoprotein
gh
escap
mutant
unstabl
cultur
absenc
antigh
neutral
antibodi
display
resist
phenotyp
number
distinct
neutral
antibodi
polyclon
serum
gh
biochem
analysi
reveal
escap
mutant
display
mark
decreas
amount
gh
express
surfac
interestingli
mechan
resist
would
consist
larg
differ
suscept
neutral
clinic
hcmv
isol
might
mechan
viru
persist
presenc
neutral
antibodi
serum
antibodi
occup
inde
play
major
role
neutral
suggest
regul
surfacespecif
molecul
certain
virus
may
common
mechan
neutral
resist
current
thought
howev
case
hcmv
may
necessari
cultur
fresh
clinic
isol
presenc
neutral
antibodi
observ
effect
sinc
passag
would
allow
rapid
revers
wild
type
occup
model
also
suggest
fab
fragment
may
neutral
viral
particl
less
effici
correspond
whole
antibodi
steric
hindranc
fab
provid
significantli
reduc
level
gener
differ
found
neutral
potenc
whole
igg
fab
explain
differ
avid
review
parren
burton
exampl
literatur
howev
indic
loss
steric
hindranc
may
also
play
role
decreas
icenogl
et
al
show
treatment
neutral
polioviru
particl
low
occup
occup
order
antibodi
molecul
per
polioviru
particl
reduc
infect
viru
stock
papain
remov
igg
fc
tail
reactiv
infect
shown
fab
fragment
still
bound
immunolog
textur
antivir
activ
antibodi
virion
howev
addit
antiantibodi
reduc
infect
initi
neutral
level
icenogl
et
al
similar
observ
made
emini
et
al
paramyxoviru
merz
et
al
shown
antihn
antibodi
complet
neutral
viru
wherea
fab
fragment
could
caus
partial
neutral
rel
larg
fraction
nonneutraliz
viru
remain
neutral
mechan
antibodi
appear
involv
aggregr
crosslink
exclud
basi
differ
agreement
model
propos
shown
neutral
potenc
mab
arteriviru
porcin
reproduct
respiratori
syndrom
viru
prrsv
correl
occup
potent
neutral
mab
stain
virion
immunoelectron
microscopi
strongli
weakli
neutral
mab
weiland
et
al
occup
model
may
final
explain
reduct
neutral
rate
function
time
kinet
experi
virus
dens
decor
antibodi
molecul
reaction
rate
start
decreas
incom
antibodi
steric
hinder
antibodi
alreadi
bound
viru
steric
hindranc
shown
exist
kinet
neutral
experi
herp
simplex
viru
hsv
perform
ash
notkin
author
demonstr
drop
neutral
rate
constant
neutral
progress
magnitud
correl
level
sensit
ash
notkin
kinet
neutral
studi
use
hsv
presensit
neutral
antibodi
furthermor
show
neutral
rate
constant
strongli
reduc
subsequ
neutral
reaction
perform
whole
antibodi
mildli
reduc
perform
fab
fragment
ash
et
al
therefor
condit
use
antibodi
alreadi
bound
virion
reduc
bind
rate
whole
antibodi
rel
smaller
fab
fragment
presum
steric
hindranc
mechan
shown
attach
igg
molecul
lead
neutral
picornaviru
particl
particular
bind
igg
molecul
hrv
prevent
attach
target
cell
therebi
neutral
viru
colonno
et
al
icenogl
et
al
smith
et
al
visual
bind
small
number
igg
molecul
surfac
picornaviru
particl
impact
virusreceptor
interact
cell
surfac
prepar
molecular
model
picornaviru
low
number
antibodi
bound
polioviru
capsid
model
coordin
protein
data
bank
pdb
berman
et
al
entri
et
al
antibodi
human
model
pdb
entri
harri
et
al
coordin
erica
ollmann
saphir
person
commun
immunolog
sanner
et
al
use
c
alpha
atom
radiu
reduc
viral
surfac
million
triangl
viral
surfac
cover
antibodi
calcul
python
sanner
use
cylind
radiu
penetr
viral
capsid
surfac
model
visual
av
pmv
artist
impress
igg
domain
movement
render
adob
photoshop
diagram
fig
three
igg
molecul
shown
interact
visibl
half
surfac
area
picornaviru
particl
level
coat
close
predict
neutral
viru
consider
rotat
flexibl
fc
region
dimens
nm
demonstr
one
igg
molecul
fig
take
flexibl
fc
translat
flexibl
antigenbound
fab
fragment
account
antibodi
could
thought
hinder
attach
viru
cellular
receptor
signific
area
surround
antigenbind
site
shown
fig
initi
product
infect
requir
interact
viru
number
receptor
molecul
local
area
see
also
fig
envis
bind
rel
small
number
antibodi
molecul
picornaviru
particl
effect
interrupt
attach
initi
infect
via
steric
hindranc
geometr
constraint
antibodi
influenza
viru
neuraminidas
na
matrix
protein
use
exampl
bind
nonneutr
antibodi
surfac
influenza
virus
contain
three
type
spike
protein
name
ha
na
insert
host
cellderiv
membran
murphi
webster
wherea
antibodi
ha
neutral
influenza
antibodi
na
kilbourn
et
al
webster
laver
zebede
lamb
presenc
antibodi
na
howev
viru
growth
vitro
vivo
reduc
indic
antibodi
recogn
protein
surfac
viru
infect
cell
activ
observ
like
result
reduc
viru
releas
antibodymedi
destruct
infect
cell
murphi
et
al
webster
laver
zebede
lamb
absenc
neutral
activ
antibodi
na
explain
abund
distribut
viral
surfac
direct
agreement
occup
hypothesi
na
protein
far
less
abund
viral
surfac
ha
protein
gener
four
five
time
ha
na
spike
na
spike
furthermor
seem
organ
patch
viru
usual
contain
copi
protein
lamb
krug
murphi
webster
therefor
although
antibodi
na
may
bind
protein
viral
immunolog
bind
averag
igg
moleculespicornaviru
particl
result
neutral
number
bound
antibodi
molecul
prevent
attach
hrv
target
cell
surfac
calcul
describ
sanner
et
al
diagram
kindli
prepar
erica
ollmann
saphir
surfac
maximum
level
occup
achiev
rel
low
like
remain
level
requir
inhibit
infect
reminisc
observ
minor
acidinduc
form
rabi
spike
protein
describ
raux
et
al
mani
instanc
virus
particularli
retrovirus
incorpor
nonvir
host
cellderiv
protein
viral
envelop
describ
shown
incorpor
hla
class
class
ii
molecul
arthur
et
al
arthur
et
al
capobianchi
et
al
gelderblom
et
al
hoxi
et
al
orenta
hildreth
saarlo
et
al
simian
immunodefici
viru
siv
fiv
furthermor
may
also
incorpor
hla
antigen
arthur
et
al
lee
et
al
may
import
consequ
macaqu
immun
human
cell
hladr
exampl
protect
challeng
siv
grown
human
host
cell
arthur
et
al
stott
suggest
cellular
adhes
molecul
associ
may
function
increas
adher
target
cell
thu
enhanc
viru
entri
particularli
wellstudi
exampl
rizzuto
sodroski
antibodi
host
cellderiv
molecul
neutral
activ
exampl
virion
complet
neutral
antibodi
interestingli
neutral
antibodi
activ
observ
compar
magnitud
classic
neutral
neutral
effect
therefor
far
greater
explain
loss
adhes
provid
virion
contact
cognat
receptor
target
cell
rizzuto
sodroski
antibodi
hla
class
ii
shown
neutral
siv
neutral
suscept
appear
determin
number
hla
molecul
present
virion
vzorov
compan
incorpor
influenza
viru
ha
molecul
phenotyp
mix
siv
virion
furthermor
render
virion
suscept
neutral
antibodi
influenza
ha
vzorov
compan
also
observ
phenotyp
mix
virion
vsv
fpv
sendai
measl
viru
kimura
wild
et
al
wild
et
al
zavada
rosenbergova
discuss
neutral
virus
antibodi
foreign
protein
viral
surfac
support
occup
model
clearli
virus
neutral
bind
antibodi
site
viral
surfac
directli
serv
function
infecti
process
eg
influenza
ha
siv
coat
viral
surfac
antibodi
molecul
subsequ
steric
interfer
virionhost
cell
interact
requir
initi
infect
attract
hypothesi
explain
observ
immunolog
interrupt
viral
infect
primarili
mediat
occup
steric
hindranc
mechan
propos
bind
antibodi
viral
receptor
target
cell
also
inhibit
initi
infect
would
predict
abil
antireceptor
antibodi
inhibit
infect
would
also
function
occup
mostli
independ
epitop
recogn
one
best
studi
exampl
probabl
inhibit
infect
antibodi
primari
receptor
molecul
four
iglik
domain
first
two
domain
project
cell
surfac
connect
hing
last
two
domain
suggest
lie
parallel
cellular
membran
wu
et
al
site
map
first
membranedist
domain
artho
et
al
larg
array
mab
distinct
epitop
studi
abil
inhibit
bind
cell
infect
antibodi
fact
found
inhibit
infect
healey
et
al
sattentau
et
al
interest
even
antibodi
map
third
domain
affect
interact
effect
inhibit
infect
comparison
mab
first
third
domain
indic
antibodi
inhibit
syncytium
format
rang
isol
similar
potenc
inhibit
infect
requir
bind
satur
avail
bind
site
target
cell
surfac
achiev
inhibit
correl
regul
experi
healey
et
al
potenc
mab
third
domain
noteworthi
given
domain
requir
infect
shown
replac
last
two
domain
retent
receptor
activ
beding
et
al
one
antibodi
probabl
bind
domain
inhibit
infect
howev
may
reflect
rel
poor
affin
antibodi
healey
et
al
truneh
et
al
one
antibodi
fourth
domain
appear
block
infect
healey
et
al
truneh
et
al
even
though
antibodi
third
domain
inhibit
infect
appear
inhibit
virion
bind
cell
healey
et
al
ugolini
et
al
interestingli
shown
antibodi
irrespect
epitop
recogn
abl
interrupt
major
histocompat
complex
mhc
class
iidepend
cell
activ
similar
inhibitori
activ
signific
inhibit
occur
nearsatur
antibodi
concentr
merkenschlag
et
al
studi
describ
appear
show
inhibit
infect
antibodi
depend
satur
avail
bind
site
mostli
independ
epitop
recogn
howev
differ
immunolog
exist
antibodi
viru
abil
inhibit
viruscel
bind
wherea
neutral
antibodi
inhibit
viru
attach
antibodi
bind
direct
vicin
highaffin
bind
site
antibodi
moredist
epitop
includ
first
domain
inhibit
attach
truneh
et
al
ugolini
et
al
may
antibodi
affin
play
role
observ
differ
inhibitori
mab
test
higher
affin
noninhibitori
mab
healey
et
al
truneh
et
al
altern
may
consequ
differ
antibodi
coat
densiti
spike
densiti
viru
therefor
antibodi
coat
densiti
sever
order
magnitud
greater
receptor
result
antibodi
coat
densiti
target
cell
therefor
conceiv
viru
dens
coat
dens
antibodi
approach
target
cell
suffici
initi
bind
wherea
virus
inhibit
approach
separ
cluster
molecul
antibodi
attach
epitop
distant
bind
site
presum
howev
antibodi
attach
perturb
necessari
spatial
organ
multipl
envelopereceptor
contact
conform
chang
requir
initi
product
infect
event
notabl
suggest
antibodi
interrupt
precis
spatial
organ
cell
receptor
accessori
molecul
requir
trigger
cell
prolifer
merkenschlag
et
al
follow
bind
requir
interact
chemokin
receptor
belong
seventransmembran
gcoupl
receptor
famili
obligatori
coreceptor
entri
target
cell
larg
number
chemokin
receptor
serv
coreceptor
entri
major
isol
use
either
major
coreceptor
see
berger
review
recent
studi
investig
inhibit
infect
antibodi
number
epitop
lee
et
al
antibodi
second
extracellular
loop
epitop
mab
effect
inhibit
infect
chemokin
bind
receptor
antibodi
studi
direct
differ
epitop
epitop
nterminu
epitop
involv
multipl
loop
block
infect
poorli
vari
abil
inhibit
chemokin
bind
receptor
mab
nterminu
block
bind
better
chemokin
bind
revers
found
antibodi
epitop
affin
antibodi
vari
equal
greater
mab
case
lee
et
al
interestingli
found
may
exist
multipl
conform
form
cell
surfac
mab
antibodi
strongest
neutral
activ
recogn
epitop
express
much
greater
proport
molecul
mab
test
appear
bind
fraction
molecul
express
immunolog
lee
et
al
therefor
correl
inhibit
infect
occup
bind
site
exist
similar
studi
discuss
suggest
antibodi
effect
inhibit
infect
recogn
subset
molecul
cell
surfac
therefor
satur
potenti
coreceptor
bind
molecul
bind
antibodi
viral
surfac
may
lead
activ
complement
depend
isotyp
antibodi
space
epitop
recogn
complement
activ
may
lead
viru
inactiv
subneutr
concentr
number
envelop
virus
includ
hcmv
vaccinia
viru
smith
spiller
et
al
carri
complement
regulatori
molecul
surfac
acquir
host
cell
membran
bud
eg
recruit
plasma
attach
envelop
glycoprotein
case
factor
h
saifuddin
et
al
saifuddin
et
al
stoiber
et
al
sullivan
et
al
regulatori
molecul
promot
resist
virion
virolysi
inhibit
full
activ
complement
cascad
therebi
provid
viru
mean
escap
inactiv
bind
rel
low
amount
antibodi
primari
isol
found
resist
tcla
virus
complementmedi
virolysi
saifuddin
et
al
spear
et
al
sullivan
et
al
resist
primari
isol
virolysi
found
directli
correl
poor
exposur
antibodi
bind
site
primari
viru
envelop
takefman
et
al
differ
note
primari
isol
grown
pbmc
vitro
plasma
viru
sensit
complementmedi
neutral
sullivan
et
al
sullivan
et
al
takefman
et
al
plasma
viru
consider
sensit
antibodydepend
complementmedi
virolysi
sullivan
et
al
takefman
et
al
explan
found
low
express
level
complement
regulatori
factor
particular
plasma
virion
surfac
compar
primari
isol
virion
sullivan
et
al
diminish
express
complement
regulatori
molecul
plasma
virion
may
explain
decreas
express
lymphocyt
infect
individu
sinc
viral
membran
deriv
cell
membran
lederman
et
al
weiss
et
al
virus
orthopoxviru
herpesviru
express
viral
complement
regulatori
molecul
either
surfac
solubl
form
may
contribut
viral
evas
eg
fodor
et
al
kotwal
et
al
rother
et
al
tortorella
et
al
orthopoxvirus
use
strategi
first
eev
respons
celltocel
longrang
spread
parren
burton
orthopoxviru
infect
blasco
moss
express
viral
protein
membran
homolog
complement
control
protein
may
provid
protect
complementmedi
virolysi
eev
engelstad
et
al
isaac
et
al
vanderplasschen
et
al
vaccinia
viru
cowpox
variola
viru
secret
complement
control
protein
inhibit
complement
activ
via
inhibit
convertas
activ
kotwal
et
al
rosengard
et
al
tortorella
et
al
virion
coat
antibodi
may
elimin
phagocytosi
follow
inactiv
intracellular
compart
within
phagocyt
process
describ
picornaviru
footandmouth
diseas
viru
fmdv
fmdv
sensit
antibodi
subneutr
concentr
activ
phagocytos
vitro
monocyt
macrophag
mccullough
et
al
phagocytosi
vivo
furthermor
appear
play
role
protect
fdmv
infect
see
antibodi
bind
effect
viral
protein
express
surfac
infect
cell
may
trigger
complementmedi
cytotox
cmc
adcc
therebi
provid
protect
viral
infect
vivo
antibodi
isotyp
space
epitop
import
paramet
effici
induct
effector
function
antibodi
domin
human
igg
isotyp
bind
well
igg
fc
receptor
capabl
activ
complement
via
classic
pathway
burton
woof
parren
cmc
adcc
mediat
neutral
antibodi
direct
viral
protein
also
express
virion
well
nonneutr
antibodi
direct
viral
protein
exclus
express
infect
cell
role
cmc
adcc
protect
viral
infect
discuss
specif
exampl
gener
howev
may
expect
neutral
antibodi
provid
stronger
protect
nonneutr
antibodi
former
act
free
virion
well
infect
cell
see
number
virus
hcmv
varicellazost
viru
vzv
express
virallyencod
fc
receptor
surfac
suggest
virus
decor
antibodi
use
receptor
bind
fc
therebi
obscur
part
immunoglobulin
ig
molecul
cellular
fc
receptor
complement
lubinski
et
al
tortorella
et
al
inde
would
seem
effect
mechan
virion
neutral
antibodi
bound
low
occup
may
escap
inactiv
vivo
immunolog
polymer
iga
igm
involv
mucos
immun
may
make
use
special
rout
neutral
virus
prevent
viral
entri
host
antibodi
activ
transport
mucos
epithelium
bind
polymer
ig
receptor
may
transport
contact
neutral
transcytos
virus
sendai
viru
ad
apic
side
epitheli
cell
monolay
shown
interact
intracellularli
polymer
iga
ad
basolater
viral
titer
reduc
cellular
supernat
lysat
fujioka
et
al
manzanec
et
al
manzanec
et
al
demonstr
neutral
influenza
viru
via
similar
mechan
manzanec
et
al
review
kato
et
al
studi
bomsel
et
al
shown
transcytosi
primari
isol
tight
epithelium
block
dimer
immun
iga
igm
shown
basolater
intern
antibodi
met
transcytos
virion
intracellular
compart
therebi
redirect
virion
back
mucos
compart
bomsel
et
al
although
affin
virion
polyclon
dimer
iga
igm
purifi
serum
infect
individu
like
low
effici
bind
may
occur
multival
interact
rel
high
concentr
within
intracellular
compart
polymer
iga
igm
therefor
may
bind
viru
intracellular
compart
neutral
infect
redirect
transcytosi
number
mechan
describ
antivir
activ
vitro
may
oper
vivo
summar
fig
includ
mechan
act
upon
free
virion
neutral
act
upon
infect
cell
cmc
adcc
discuss
view
neutral
mediat
antibodi
bind
envelop
molecul
virion
surfac
effect
coat
virion
prevent
viral
attach
andor
fusion
antibodi
also
bind
envelop
molecul
express
surfac
infect
cell
therebi
trigger
elimin
cell
fcmediat
effector
system
nonneutr
antibodi
similarli
bind
viral
protein
express
infect
cell
produc
antivir
activ
protein
includ
envelop
molecul
form
express
express
rel
low
amount
virion
final
evid
special
instanc
bind
antibodi
infect
cell
appear
suppress
viral
replic
without
lead
cell
destruct
mani
virus
correl
level
serum
antibodi
neutral
activ
vitro
vivo
protect
antibodi
level
respons
protect
mere
correl
classic
approach
immunolog
antivir
activ
antibodi
separ
activ
virion
activ
infect
cell
neutral
mediat
antibodi
bind
well
molecul
virion
surfac
effect
coat
virion
therebi
prevent
viral
entri
antibodymedi
effector
mechan
complementmedi
lysi
phagocytosi
aid
viru
inactiv
antibodi
envelop
spike
envelop
viru
may
also
bind
envelop
molecul
surfac
infect
cell
therebi
trigger
elimin
cell
fcmediat
effector
mechan
nonneutr
antibodi
similarli
bind
viral
protein
infect
cell
produc
antivir
activ
protein
includ
molecul
form
express
express
low
amount
virion
question
passiv
transfer
serum
antibodi
immun
anim
anim
determin
protect
provid
mani
case
chanock
et
al
passiv
transfer
provid
protect
diseas
also
evid
human
abil
passiv
transfer
antibodi
protect
diseas
aris
number
viral
pathogen
includ
rsv
hepat
viru
measl
viru
polioviru
vzv
variola
viru
chanock
et
al
case
determin
whether
antibodi
provid
immunolog
textur
antivir
activ
antibodi
steril
protect
may
mani
case
antibodi
limit
infect
cellular
innat
immun
also
requir
protect
diseas
antivir
monoclon
antibodi
permit
quantit
investig
relationship
neutral
vitro
protect
vivo
clearli
comparison
present
difficulti
even
similar
antivir
mechan
oper
vitro
vivo
latter
involv
varieti
factor
difficult
control
may
easili
reproduc
vitro
instanc
host
cell
type
use
vitro
may
differ
activationmatur
state
cell
type
infect
vivo
fact
cell
line
often
use
vitro
factor
molecul
may
influenti
vivo
absent
vitro
virus
distinct
characterist
may
select
vivo
vitro
lead
aberr
conclus
lactat
dehydrogenaseelev
viru
ldv
strike
exampl
discuss
thu
caution
comparison
appropri
nevertheless
import
ask
well
neutral
mab
vitro
correl
protect
activ
vivo
point
good
correl
necessarili
prove
mechan
vitro
neutral
vivo
protect
sinc
neutral
strongli
correl
virion
bind
mechan
strongli
correl
bind
eg
complementmedi
virolysi
could
theori
respons
howev
mani
case
vivo
activ
shown
independ
fc
part
igg
molecul
impli
neutral
block
mechan
probabl
paramount
report
gauduin
et
al
parren
et
al
parren
et
al
steril
protect
hupblscid
mice
viru
challeng
laboratoryadapt
primari
virus
requir
serum
mab
concentr
one
two
order
magnitud
greater
requir
vitro
neutral
concentr
correspond
essenti
complet
viru
neutral
vitro
tcla
virus
much
easier
neutral
vitro
correspondingli
much
easier
protect
vivo
similar
find
regard
relationship
neutral
protect
appar
challeng
macaqu
chimer
sivhiv
shiv
virus
baba
et
al
mascola
et
al
shibata
et
al
one
instanc
mucos
challeng
partial
protect
describ
serum
mab
concentr
correspond
neutral
vitro
mascola
et
al
recent
howev
found
protect
mucos
challeng
shiv
viru
requir
mab
concentr
capabl
neutral
essenti
challeng
viru
parren
et
al
fact
result
macaqu
model
close
parallel
scid
mous
studi
sinc
effector
system
like
consider
effici
former
latter
model
result
impli
effector
system
essenti
protect
immunolog
textur
research
biolog
tumor
induc
murin
leukemia
virus
mulv
shown
antibodi
mulv
antigen
express
surfac
malignantinfect
cell
provid
protect
tumor
growth
antibodi
gross
viru
cell
surfac
antigen
provid
complet
protect
challeng
syngen
gross
cell
surfac
antigenposit
leukemia
cell
lysi
cell
cmc
demonstr
vitro
old
et
al
gross
viru
cell
surfac
antigen
later
found
ident
mulv
glycogag
glycosyl
version
gag
polyprotein
express
cell
surfac
incorpor
virion
ledbett
nowinski
note
antisera
use
old
et
al
also
contain
neutral
antibodi
gross
viru
uncertain
protect
effect
mediat
antibodi
glycogag
similarli
howev
nonneutr
mab
moloney
mulv
mmulv
react
friendmoloneyrausch
viru
groupspecif
antigen
express
surfac
infect
cell
virion
protect
tumor
growth
lamon
et
al
pincu
et
al
recent
show
nonneutr
antibodi
mulv
glyco
gag
delay
onset
mulv
pathogenesi
antibodi
gag
also
delay
diseas
onset
fab
fragment
albeit
less
effect
indic
clearanc
infect
cell
fcmediat
effector
function
wholli
explain
protect
effect
shown
mulv
glycogag
play
import
role
viral
spread
pathogenesi
corbin
et
al
porti
et
al
occup
glycogag
cell
surfac
antibodi
form
whole
igg
well
fab
fragment
may
therefor
abl
interfer
glycogag
function
therebi
provid
protect
limit
viru
spread
without
directli
clear
infect
cell
protect
mulv
challeng
expect
also
provid
antibodi
envelop
effect
antibodi
gag
show
good
correl
neutral
titer
degre
protect
provid
pincu
et
al
viru
use
studi
recombin
friend
mulv
fmulv
env
gene
neurovirul
wildmous
ecotrop
viru
casbr
insert
antibodi
envelop
also
effect
fmulv
fmulvinfect
cell
transfer
postchalleng
requir
fc
portion
protect
reduct
frequenc
fmulvproduc
cell
leukem
spleen
could
induc
neutral
mab
mediat
cmc
other
britt
chesebro
passiv
transfer
neutral
antibodi
fmulv
envelop
furthermor
protect
fmulv
pathogenesi
whole
antibodi
f
ab
fragment
collin
et
al
friend
viru
use
model
studi
mechan
immun
live
attenu
retrovirus
protect
subsequ
challeng
virul
strain
model
use
complex
interest
immunolog
one
model
immunosuppress
retroviru
induc
diseas
immunocompet
mice
challeng
perform
combin
two
virus
nonpathogen
replicationcompet
helper
viru
fmulv
contain
requir
immunolog
determin
replicationdefect
viru
spleen
focusform
viru
sffv
requir
pathogen
adult
mice
dittmer
et
al
immun
attenu
fmulv
elicit
highli
protect
immun
respons
shown
protect
immun
respons
involv
cell
well
b
cell
compon
protect
respons
could
transfer
mice
combin
three
cell
popul
transplant
dittmer
et
al
neutral
antibodi
present
respons
level
concentr
requir
provid
steril
immun
nevertheless
appear
play
import
role
observ
protect
diseas
evidenc
follow
first
protect
plasma
viremia
complet
correl
presenc
fmulv
neutral
serum
antibodi
dittmer
et
al
second
passiv
transfer
fmulv
neutral
antibodi
level
observ
immun
protect
pathogen
anim
receiv
antibodi
recov
friend
virusinduc
diseas
dittmer
et
al
third
complet
protect
correl
presenc
virusneutr
antibodi
well
prime
cytotox
lymphocyt
ctl
develop
protect
persist
infect
particular
develop
postimmun
appear
neutral
antibodi
dittmer
et
al
seri
experi
indic
neutral
antibodi
level
requir
induc
steril
protect
play
critic
role
protect
retroviru
classic
earli
studi
lefrancoi
describ
panel
mab
glycoprotein
g
vsv
neutral
mab
complet
protect
mice
rel
high
dose
nonneutr
mab
also
protect
although
less
effect
neither
class
mab
protect
given
earli
hr
postinfect
nonneutr
mab
bound
much
less
effect
neutral
mab
intact
virion
howev
nonneutr
mab
could
lyse
infect
cell
presenc
complement
f
ab
fragment
nonneutr
mab
protect
wherea
fragment
neutral
mab
protect
suggest
nonneutr
mab
like
mediat
protect
via
fcdepend
effector
function
activ
infect
cell
behavior
f
ab
fragment
neutral
mab
suggest
effector
system
crucial
protect
activ
antibodi
interest
featur
studi
evid
provid
certain
form
envelop
protein
present
surfac
infect
cell
essenti
absent
virion
immunolog
textur
one
detail
comparison
neutral
protect
bachmann
et
al
describ
properti
larg
panel
mab
singl
antigen
site
vsvg
author
report
good
correl
neutral
abil
antibodi
affin
avid
intact
viru
particl
howev
two
paramet
report
correl
abil
antibodi
protect
scid
mice
viral
challeng
protect
said
depend
simpli
upon
minimum
serum
concentr
antibodi
independ
affin
howev
antibodi
studi
fell
rather
narrow
affin
rang
correspond
free
energi
bind
rang
kcalmol
inde
minimum
serum
concentr
complet
protect
mice
occur
correspond
narrow
rang
roughli
gml
antibodi
significantli
lower
affin
found
protect
mice
concentr
use
contradict
thesi
neutral
protect
correl
interpret
threshold
effect
protect
behavior
antibodi
predict
law
mass
action
one
antibodi
somewhat
lower
affin
appar
disproportion
poor
neutral
abil
abl
protect
challeng
mice
approxim
gml
view
latter
antibodi
one
potenti
offer
signific
challeng
correl
affinityneutr
protect
earli
studi
investig
mab
envelop
protein
sindbi
viru
semliki
forest
viru
sfv
venezuelan
equin
encephalomyel
vee
viru
studi
sindbi
viru
schmaljohn
et
al
neutral
nonneutr
antibodi
protect
latter
shown
bind
infect
cell
virion
suggest
complementmedi
lysi
infect
cell
might
crucial
later
studi
schmaljohn
et
al
confirm
protect
epitop
present
infect
cell
surfac
virion
neutral
nonneutr
mab
protein
sfv
shown
protect
mice
lethal
infect
although
former
effect
much
lower
dose
boer
et
al
protect
observ
neutral
mab
concentr
expect
satur
challeng
viru
good
correl
efficaci
mab
respect
vitro
neutral
protect
neutral
nonneutr
mab
bound
infect
cell
promot
complementmedi
lysi
although
neutral
mab
effect
remov
fc
part
neutral
mab
reduc
neutral
capac
roughli
compar
reduct
protect
efficaci
remov
fc
part
nonneutr
mab
caus
complet
loss
protect
abil
result
immunolog
textur
antivir
activ
antibodi
consist
crucial
role
fcmediat
effector
function
protect
nonneutr
antibodi
lesser
role
neutral
antibodi
potent
neutral
mab
found
protect
mice
lethal
challeng
vee
mathew
et
al
howev
correspond
f
ab
fragment
protect
although
neutral
potenc
parent
mab
import
fc
effector
function
protect
infer
although
much
shorter
halflif
f
ab
fragment
vivo
may
contribut
ineffici
nonneutr
mab
found
protect
much
higher
concentr
presum
bind
infect
cell
sinc
antibodi
bind
intact
virion
passiv
administ
immun
serum
matern
antibodi
antienvelop
glycoprotein
mab
shown
protect
mice
lethal
challeng
lymphocyt
choriomening
viru
lcmv
baldridg
buchmeier
protect
mab
requir
concentr
lead
essenti
complet
neutral
viru
vitro
appear
complet
protect
requir
antibodi
activ
free
virion
also
infect
cell
thu
f
ab
fragment
protect
mab
retain
neutral
activ
vitro
protect
vivo
furthermor
mab
potent
neutral
activ
protect
antibodi
protect
activ
infect
cell
involv
complement
sinc
mice
also
protect
mab
interest
advantag
passiv
transfer
neutral
antibodi
lcmv
infect
effect
reduc
viral
challeng
attenu
subsequ
ctl
respons
wright
buchmeier
crucial
modul
potenti
destruct
effect
overvigor
cellmedi
immun
respons
sever
earli
studi
look
abil
mab
protect
mice
lethal
challeng
murin
hepat
virus
mhv
abil
panel
mab
given
ip
protect
mice
intracerebr
challeng
show
potent
neutral
mab
specif
glycoprotein
protect
high
dose
buchmeier
et
al
infect
block
complet
viral
load
liver
brain
central
nervou
system
cn
lower
unprotect
mice
demyelin
rather
fatal
encephalomyel
result
one
potent
neutral
mab
protect
howev
mab
recogn
epitop
subject
rapid
neutral
escap
dalziel
et
al
challeng
viru
may
contain
escap
variant
unusu
fit
vivo
j
buchmeier
immunolog
textur
parren
burton
person
commun
nonneutr
membran
glycoprotein
antin
nucleoprotein
mab
nonprotect
anoth
studi
investig
activ
mab
specif
protein
wege
et
al
three
mab
potent
neutral
viru
inhibit
cell
fusion
bound
well
infect
cell
protect
intracerebr
challeng
mab
includ
neutral
weakli
neutral
bound
well
infect
cell
protect
studi
assess
activ
mab
one
neutral
presenc
complement
mab
protect
nonneutr
mab
protect
neutral
mab
equal
effect
decompl
mice
suggest
complement
crucial
protect
monitor
viral
load
liver
spleen
brain
allow
effect
mab
iv
challeng
mice
explor
quantit
nakanaga
et
al
protect
lethal
challeng
provid
potent
neutral
mab
nonneutr
mab
nonneutr
antinucleoprotein
np
mab
howev
neutral
mab
result
much
lower
viral
load
tissu
infect
anim
particularli
brain
viral
titer
order
magnitud
lower
neutral
mabtreat
nonneutr
mabtreat
mice
furthermor
neutral
mab
abl
protect
challeng
dose
pfu
compar
usual
dose
pfu
protect
antinp
presum
mediat
activ
infect
cell
express
np
surfac
confirm
challeng
lecomt
et
al
comparison
potent
neutral
igg
correspond
f
ab
fab
fragment
show
three
molecul
could
neutral
neurotrop
viru
three
could
protect
mice
lethal
intracerebr
challeng
high
dose
produc
serum
titer
approxim
time
neutral
titer
vitro
effici
protect
given
molecul
correl
well
potenc
neutral
affin
antigen
lamarr
talbot
singlechain
fv
fragment
mab
could
neutral
viru
ineffect
protect
presum
extrem
short
vivo
halflif
min
lamarr
et
al
recent
studi
wilson
et
al
describ
vitro
vivo
effect
panel
mab
envelop
glycoprotein
ebola
viru
major
mab
protect
mice
challeng
mouseadapt
ebola
viru
none
protect
antibodi
neutral
viru
plaqu
assay
absenc
complement
presenc
complement
subset
antibodi
neutral
viru
antibodi
complet
protect
observ
serum
concentr
approxim
order
magnitud
greater
immunolog
textur
antivir
activ
antibodi
concentr
requir
neutral
vitro
caveat
note
neutral
carri
plaqu
viru
although
infecti
particl
nonplaqu
reveal
correspond
challeng
dose
pfu
viru
use
potent
human
neutral
antiebola
antibodi
parren
et
al
found
protect
guinea
pigadapt
viru
guinea
pig
model
requir
serum
antibodi
concentr
correspond
essenti
complet
viru
neutral
vitro
maruyama
et
al
parren
et
al
case
viral
challeng
much
higher
pfu
ld
previou
exampl
pfu
ld
earli
studi
show
neutral
mab
envelop
glycoprotein
nonneutr
antibodi
nonstructur
glycoprotein
yellow
fever
yf
viru
could
protect
mice
lethal
intracerebr
challeng
gould
et
al
schlesing
chapman
neutral
mab
effect
could
protect
neurovirul
strain
yf
viru
antin
mab
ineffect
recent
shown
f
ab
fragment
strongli
neutral
mab
equal
effect
neutral
mediat
protect
vivo
schlesing
chapman
howev
incub
f
ab
viru
complex
rabbit
igg
antimous
igg
result
protect
contrast
correspond
rabbit
f
ab
fragment
afford
protect
addit
switch
variant
suggest
specif
parent
fc
effect
protect
parent
result
impli
role
fcmediat
effector
system
protect
yf
recent
studi
forthal
et
al
develop
humor
immun
tickborn
enceph
viru
tbev
provid
novel
insight
antibodi
virion
infect
cell
import
passiv
transfer
polyclon
neutral
antibodi
dose
expect
complet
neutral
viru
vitro
protect
mice
lethal
tbev
challeng
howev
despit
high
dose
use
protect
steril
viral
replic
occur
transfer
sera
mice
could
confer
complet
protect
diseas
mice
interestingli
transfer
tenrich
spleen
cell
mice
could
confer
protect
mice
specif
transfer
antibodi
shown
nonstructur
protein
absent
virion
impli
antibodi
activ
infect
cell
confer
protect
antibodydepend
enhanc
ade
tbev
demonstr
vitro
suggest
postexposur
ig
prophylaxi
wide
use
nonvaccin
individu
bitten
tick
area
viru
endem
might
worsen
outcom
infect
howev
studi
immunolog
kreil
eibl
note
vivo
relev
antibodymedi
enhanc
infect
uncertain
mani
case
flaviviru
dengu
viru
howev
form
clear
exampl
viru
strong
vivo
enhanc
antibodi
envelop
glycoprotein
demonstr
halstead
halstead
passiv
transfer
immun
rabbit
antiigg
shown
protect
mice
lethal
challeng
hsv
type
corneal
inocul
subcutan
inocul
oak
lausch
protect
serum
neutral
titer
approxim
correspond
f
ab
prepar
equal
effect
neutral
vitro
protect
vivo
howev
interestingli
igg
prepar
show
activ
establish
infect
anoth
model
infect
mice
inocul
viru
footpad
treat
hr
later
singl
dose
immun
rabbit
igg
five
daili
dose
correspond
f
ab
prepar
mckendal
treatment
led
serum
neutral
antibodi
titer
igg
treatment
markedli
f
ab
treatment
moder
reduc
footpad
viral
titer
viral
spread
sciatic
nerv
spinal
cord
establish
latenc
igg
effect
also
appar
mice
studi
look
activ
immun
mous
human
igg
hsv
nude
mice
hayashida
et
al
rel
high
concentr
antibodi
ml
serum
neutral
titer
given
ip
requir
inhibit
develop
skin
lesion
prolong
surviv
lethal
infect
mice
purifi
f
ab
fragment
ineffect
even
given
repeatedli
maintain
neutral
titer
igg
effect
mice
result
consist
notion
adcc
becom
crucial
protect
hsv
steril
protect
provid
challeng
mani
studi
look
abil
mab
protect
hsv
infect
earli
paper
show
neutral
antigd
gc
mab
nonneutr
antigd
gc
gb
gd
ge
mab
could
protect
lethal
footpad
challeng
mice
balachandran
et
al
dix
et
al
latter
studi
found
mixtur
mab
efficaci
correspond
roughli
sum
individu
mab
protect
equal
appar
mice
good
correl
report
protect
titer
nonneutr
mab
adcc
assay
suggest
adcc
could
provid
protect
lethal
hsv
infect
murin
zosteriform
spread
model
infect
initi
cutan
site
spread
peripher
nervou
system
viru
reemerg
infect
region
epithelium
remot
inocul
immunolog
textur
antivir
activ
antibodi
site
model
mimic
cours
human
herpet
diseas
high
dose
mgmous
antigd
gc
one
gb
mab
offer
partial
protect
model
mester
et
al
report
protect
correl
better
vitro
adcc
neutral
activ
addit
f
ab
fab
fragment
two
protect
antigc
mab
nonprotect
investig
abil
panel
antigd
mab
protect
challeng
show
mab
neutral
viru
even
absenc
complement
effect
ishizaka
et
al
seri
mab
neutral
presenc
complement
order
efficaci
seri
switch
variant
human
neutral
antigd
mab
shown
complet
protect
nude
mice
lethal
challeng
use
high
iv
dose
gmous
mab
appli
topic
could
protect
mice
vagin
challeng
much
lower
dose
mab
ngmous
zeitlin
et
al
igg
f
ab
fragment
approxim
equival
topic
protect
abil
fab
fragment
somewhat
less
effect
detail
studi
mozdzanowska
et
al
compar
vitro
neutral
vivo
protect
activ
number
mab
influenza
viru
ha
mab
chosen
rang
neutral
activ
presenc
complement
serum
neutral
abil
differenti
enhanc
serum
antibodi
concentr
confer
protect
two
three
order
magnitud
higher
concentr
requir
neutral
vitro
presenc
complement
howev
rank
order
protect
abil
well
predict
order
neutral
abil
et
al
shown
passiv
transfer
studi
good
correl
exist
neutral
protect
fdmv
antibodi
neutral
certain
fdmv
challeng
isol
strongli
moder
provid
protect
interestingli
howev
antibodi
protect
concentr
requir
vitro
neutral
fdmv
enhanc
protect
abil
antibodi
appear
fcmediat
convers
mab
f
ab
fragment
reduc
protect
abil
wherea
neutral
abil
mostli
retain
mccullough
et
al
neutral
titer
affect
addit
complement
suggest
cmc
play
signific
role
mccullough
et
al
effect
rather
appear
due
induct
phagocytosi
sensit
viru
impair
phagocytosi
silica
treatment
abrog
enhanc
protect
silicatr
mice
neutral
antibodi
concentr
immunolog
well
neutral
titer
requir
protect
indic
absenc
phagocytosi
protect
correl
neutral
challeng
viru
like
effici
protect
fdmv
infect
neutral
antibodi
low
occup
provid
effici
phagocytosi
sensit
virion
demonstr
fdmv
vitro
mccullough
et
al
mccullough
et
al
mani
studi
look
activ
antibodi
rsv
one
antirsv
mab
clinic
use
prophylaxi
rsv
diseas
passiv
transfer
polyclon
antibodi
administ
ip
produc
serum
neutral
titer
greater
provid
steril
protect
lung
cotton
rat
challeng
rsv
princ
et
al
similarli
high
dose
antif
antig
glycoprotein
mab
reduc
viru
titer
lung
cotton
rat
challeng
rsv
undetect
level
walsh
et
al
antirsv
mab
includ
f
glycoprotein
neutral
vitro
mab
complet
protect
mice
stott
et
al
contrast
nonneutr
antig
mab
protect
scid
mice
intranas
rsv
challeng
dose
mgkg
describ
corbeil
et
al
protect
reduc
decompl
mice
suggest
complement
import
antivir
activ
bovin
rsv
two
neutral
antif
mab
administ
intratrach
rout
moder
dose
mgkg
protect
infect
wherea
nonneutr
mab
protect
thoma
et
al
antif
iga
mgkg
introduc
intranas
mice
prior
rsv
challeng
greatli
reduc
viru
titer
lung
weltzin
et
al
human
phase
iii
trial
enhanc
activ
one
mab
rel
anoth
attribut
least
part
better
neutral
abil
vitro
johnson
et
al
antivir
activ
panel
nine
mab
f
protein
sendai
viru
compar
vitro
vivo
mochizuki
et
al
none
mab
neutral
standard
assay
two
potent
neutral
presenc
complement
mab
protect
young
mice
lethal
infect
allow
thrive
term
bodi
weight
gain
given
high
dose
three
mab
show
weak
neutral
presenc
complement
also
protect
two
mab
isotyp
lead
suggest
adcc
rather
complement
might
import
protect
passiv
transfer
neutral
mab
bluetongu
viru
btv
shown
protect
mice
sheep
diseas
wherea
nonneutr
mab
protect
neutral
antibodi
titer
protect
immunolog
textur
antivir
activ
antibodi
sheep
diseas
provid
steril
immun
increas
neutral
titer
observ
day
postchalleng
result
strong
contrast
inabl
higher
neutral
antibodi
titer
clear
viru
sheep
exist
infect
letchworth
appleton
impact
antibodi
establish
infect
discuss
detail
infect
mice
certain
strain
neuropathogen
ldv
result
fatal
paralyt
diseas
interact
endogen
retrovirus
infect
anterior
horn
neuron
ldv
develop
diseas
prevent
antildv
antibodi
mechan
motor
neuron
protect
infect
ldv
unclear
addit
neutral
antibodi
also
nonneutr
polyclon
antibodi
prevent
neuron
destruct
diseas
addit
protect
occur
absenc
appar
effect
antibodi
ldv
replic
subpopul
macrophag
known
primari
permiss
host
cell
resolut
paradox
lesson
regard
abil
viral
quasispeci
mislead
chen
et
al
appear
neuropathogen
ldv
isol
contain
neuropathogen
nonneuropathogen
quasispeci
use
biolog
clone
shown
nonneuropathogen
speci
time
resist
vitro
neutral
neuropathogen
speci
antibodi
therefor
neutral
nonneuropathogen
virus
score
nonneutr
vitro
assay
antibodi
howev
neutral
neuropathogen
virus
therefor
protect
vivo
paradox
describ
appear
due
ldv
heterogen
interest
mix
viru
popul
distinct
neutral
properti
also
describ
anoth
arteriviru
prrsv
weiland
et
al
tcell
line
adapt
strain
repres
strike
exampl
studi
neutral
viral
variant
select
vitro
may
lead
aberr
conclus
respect
neutral
respons
infect
adapt
growth
cell
line
select
variant
readili
neutral
solubl
larg
spectrum
differ
mab
contrast
plasma
viru
virus
passag
primari
cultur
activ
peripher
blood
mononuclear
cell
pbmc
mostli
resist
neutral
ligand
review
parren
et
al
explan
phenomenon
may
high
express
level
heparan
sulfat
proteoglycan
surfac
cell
line
interact
may
select
virus
unusu
strongli
basic
loop
moulard
et
al
envelop
spike
tcla
virus
adopt
much
open
configur
provid
access
rang
epitop
inaccess
natur
occur
isol
consequ
sera
infect
individu
well
sera
vaccine
immun
recombin
envelop
subunit
typic
contain
high
titer
neutral
antibodi
tcla
strain
wherea
relev
titer
primari
isol
usual
poor
natur
passiv
transfer
studi
typic
viru
challeng
dose
rel
larg
ensur
control
anim
becom
infect
sometim
argu
human
infect
challeng
dose
could
smaller
protect
achiev
lower
antibodi
concentr
indic
anim
studi
exampl
siv
shiv
experi
macaqu
usual
involv
viru
challeng
dose
aid
anim
infecti
dose
howev
typic
human
challeng
dose
probabl
aid
less
sinc
frequenc
infect
less
depend
upon
natur
exposur
interpret
indic
rel
low
vaccineinduc
serum
antibodi
concentr
compar
vitro
neutral
titer
may
offer
protect
benefit
infect
thermodynam
standpoint
argument
appear
littl
merit
sinc
amount
serum
antibodi
vast
molar
excess
challeng
viru
scenario
extent
antibodi
coat
viru
therefor
neutral
determin
bind
constant
antibodi
viru
rather
number
challeng
particl
howev
studi
awar
directli
address
abil
antibodi
protect
low
challeng
dose
given
viru
exist
factor
low
dose
natur
infect
process
outsid
laboratori
complic
extrapol
anim
studi
human
categor
exclud
anatom
consider
may
also
complic
interpret
vivo
protect
data
antibodi
serum
concentr
readili
measur
part
tissu
antibodi
concentr
measur
concentr
antibodi
may
fact
respons
block
infect
tissu
site
known
possibl
high
serum
antibodi
concentr
requir
protect
instanc
reflect
difficulti
achiev
protect
antibodi
concentr
critic
tissu
site
antibodi
better
abl
other
diffus
tissu
site
may
therefor
show
enhanc
vivo
rel
vitro
activ
immunolog
although
evid
antibodi
impact
upon
number
establish
viral
infect
chanock
et
al
littl
quantit
data
relat
vivo
vitro
activ
data
review
consid
antibodi
given
day
viru
activ
establish
infect
oppos
prophylact
activ
consid
clearli
somewhat
artifici
distinct
antibodi
gener
appear
diminish
activ
infect
progress
eleg
studi
show
scid
mice
infect
influenza
day
cure
use
neutral
mab
viral
ha
close
correl
prophylact
cur
activ
mozdzanowska
et
al
data
suggest
cur
effect
mainli
due
neutral
activ
antibodi
free
viru
contribut
activ
infect
cell
conclus
support
investig
two
nonneutr
mab
one
viral
na
one
mozdzanowska
et
al
mab
reduc
pulmonari
viral
titer
establish
infect
fail
clear
infect
even
high
dose
combin
might
predict
neutral
antibodi
would
activ
viru
influenza
propag
via
celltocel
spread
cytopath
infect
cell
presenc
high
level
neutral
antibodi
eventu
termin
infect
howev
virus
propag
via
celltocel
spread
antibodi
would
expect
less
effect
sinc
higher
concentr
neutral
antibodi
gener
requir
inhibit
infect
rout
requir
inhibit
infect
free
virion
hook
et
al
pantaleo
et
al
inde
hupblscid
mous
studi
suggest
viru
replic
unhind
signific
proport
case
presenc
serum
concentr
singl
mab
larg
protect
administ
prior
viru
challeng
remaind
case
neutral
escap
occur
rapidli
show
mab
exert
pressur
viru
replic
anim
cocktail
mab
administ
high
dose
mgkg
establish
infect
neutral
escap
rapidli
appar
howev
serum
mab
concentr
wane
around
time
vitro
neutral
level
wildtyp
neutralizationsensit
viru
reemerg
suggest
escap
variant
less
fit
wild
type
establish
high
threshold
serum
antibodi
impact
upon
propag
infect
anoth
studi
show
passiv
transfer
neutral
polyclon
antisiv
antibodi
modest
effect
upon
siv
replic
macaqu
binley
et
al
effect
antibodi
establish
retroviru
infect
also
investig
fmulv
system
hasenkrug
et
al
high
dose
neutral
mab
could
induc
recoveri
success
depend
upon
presenc
immunolog
lymphocyt
result
strikingli
demonstr
abil
antibodi
two
popul
cell
work
togeth
way
fulli
understood
time
rsv
viru
name
one
might
expect
propag
via
celltocel
spread
howev
although
syncytia
observ
vitro
observ
vivo
mode
infect
propag
unclear
tracheal
epithelium
spars
infect
point
time
howev
unlik
celltocel
spread
major
mechan
spread
vivo
mcintosh
chanock
case
number
studi
shown
neutral
antibodi
therapeut
effect
earli
work
cotton
rat
model
show
passiv
administ
polyclon
immun
antibodi
result
serum
neutral
titer
rang
could
drastic
reduc
viru
titer
lung
much
factor
princ
et
al
later
work
focus
intranas
inocul
rel
small
quantiti
neutral
antibodi
found
effect
cotton
rat
mice
monkey
crow
et
al
hem
et
al
princ
et
al
princ
et
al
weltzin
et
al
therapeut
effect
could
achiev
f
ab
princ
et
al
fab
fragment
crow
et
al
neutral
antibodi
suggest
direct
result
interact
antibodi
viru
case
fab
fragment
viral
load
lung
infect
mice
could
reduc
factor
almost
littl
g
protein
introduc
intranas
number
studi
show
antibodi
highli
effect
establish
cn
infect
rodent
model
prevent
diseas
death
administr
larg
amount
hyperimmun
serum
mlmous
complet
protect
anim
ill
given
hr
follow
footpad
challeng
lubinski
et
al
time
interv
challeng
antibodi
administr
increas
incid
ill
increas
hr
hr
hr
mab
high
dose
given
hr
postexposur
similarli
shown
protect
ocular
diseas
mice
protect
occur
nonneutr
well
neutral
mab
suggest
expect
import
activ
infect
cell
protect
intracerebr
challeng
mice
yf
viru
shown
occur
even
mab
given
ip
sever
day
viru
inocul
peak
infecti
viru
titer
histopatholog
evid
infect
present
brain
nearli
complet
protect
eight
nine
anim
note
one
mab
given
dose
approxim
mgkg
day
cerebr
challeng
protect
appar
neutral
nonneutr
mab
furthermor
nonneutr
mab
shown
inhibit
viral
replic
vitro
neuroblastoma
cell
line
hint
novel
mechan
antibodi
protect
immunolog
thorough
studi
show
polyclon
antibodi
mab
protect
neural
spread
reoviru
type
dear
mice
virgin
et
al
even
given
sever
day
cerebr
footpad
challeng
instanc
potent
neutral
mab
given
approxim
mgkg
week
postchalleng
led
surviv
roughli
half
anim
infect
protect
appar
neutral
nonneutr
polyclon
antibodi
nonneutr
mab
far
less
effect
neutral
mab
serum
complement
requir
antivir
activ
attempt
investig
activ
f
ab
fragment
compar
experi
thwart
short
halflif
f
ab
even
daili
administr
maintain
serum
level
care
work
emphas
unless
f
ab
level
specif
monitor
conclus
drawn
compar
igg
f
ab
treat
caution
studi
show
high
dose
neutral
mab
protect
mice
lethal
challeng
theiler
murin
encephalomyel
viru
fujinami
et
al
neurotrop
measl
viru
liebert
et
al
given
day
hr
postexposur
respect
latter
case
nonneutr
mab
ineffect
latter
studi
provid
evid
abil
antibodi
restrict
viral
replic
insid
infect
cell
bind
viral
antigen
interest
potenti
import
phenomenon
first
describ
oldston
measl
virusinfect
cell
extens
investig
griffin
cowork
sindbi
viru
infect
neuron
levin
et
al
treatment
persist
infect
scid
mice
mab
glycoprotein
sindbi
viru
result
gradual
noncytopath
remov
viral
rna
process
independ
complement
cell
antibodi
also
clear
sindbi
viru
persist
infect
neuron
cell
cultur
isotyp
antibodi
import
bival
requir
ubol
et
al
suggest
clearanc
involv
novel
mechan
trigger
antibodi
crosslink
viral
protein
express
surfac
infect
cell
similar
mechan
propos
antibodi
activ
rabiesinfect
neural
cell
dietzschold
et
al
mechan
distinct
earlier
studi
describ
abil
antibodi
modul
antigen
express
surfac
infect
cell
therebi
reduc
effici
viru
bud
eg
chesebro
et
al
final
nonneutr
iga
mab
resolv
ongo
rotaviru
infect
appar
interact
antibodi
viru
transcytosi
burn
et
al
scid
mice
infect
rotaviru
least
month
transplant
subcutan
hybridoma
secret
mab
outer
capsid
viral
protein
major
inner
capsid
viral
protein
two
nonneutr
iga
mab
capabl
resolv
chronic
infect
mab
howev
activ
present
directli
lumin
immunolog
textur
parren
burton
side
intestin
tract
suggest
mode
action
transcytosi
describ
vitro
bomsel
et
al
manzanec
et
al
neutral
iga
mab
resolv
infect
note
correl
inactiv
infect
pathogen
antibodi
coat
extend
beyond
virus
focus
review
exampl
discuss
correl
exist
neutral
intracellular
bacterium
chlamydia
trachomati
coat
infecti
elementari
bodi
antibodi
peel
brunham
complement
may
enhanc
neutral
opson
c
trachomati
megran
et
al
passiv
transfer
antibodi
outer
surfac
protein
borrelia
burgdorferi
strongli
stain
nonpermeabil
b
burgdorferi
cell
complet
protect
mice
challeng
mbow
et
al
protect
parasit
trypanosoma
cruzi
antibodi
furthermor
correl
antibodi
bind
live
trypomastigot
immunofluoresc
heath
et
al
began
assert
gener
rule
describ
vitro
vivo
activ
antibodi
virus
discern
literatur
review
interpret
data
whole
signific
rule
much
discuss
mechan
neutral
virus
vitro
promin
opinion
antibodi
act
mani
differ
stage
infecti
process
includ
postvir
entri
target
cell
sever
differ
mechan
may
oper
concert
critic
site
virion
surfac
must
occupi
neutral
dimmock
disagre
believ
data
consist
vast
major
case
simpl
occup
model
essenti
initi
propos
macfarlan
burnet
accord
model
neutral
occur
sizabl
fraction
avail
site
virion
occupi
antibodi
lead
inhibit
viru
attach
interfer
entri
fusion
process
rel
larg
bulk
antibodi
molecul
roughli
similar
typic
envelop
spike
envelop
viru
suggest
critic
fig
model
consist
number
observ
first
shown
roughli
linear
relationship
surfac
area
viru
number
antibodi
molecul
bound
neutral
number
approxim
predict
effect
coat
virion
particl
given
immunolog
textur
fig
model
propos
interact
envelop
spike
neutral
igg
molecul
depict
drawn
scale
assum
igg
molecul
roughli
molecular
weight
monom
typic
trimer
envelop
spike
model
explain
antibodi
coat
viru
surfac
may
interrupt
infect
without
occupi
avail
bind
site
envelop
spike
igg
molecul
bound
addit
bind
site
envelop
spike
still
avail
bind
addit
antibodi
distinct
epitop
recombin
solubl
receptor
molecul
may
inhibit
antibodi
loop
exampl
inhibit
bind
solubl
b
envelop
spike
variou
number
igg
molecul
associ
coat
virion
spike
antibodi
irrespect
epitop
recogn
interfer
initi
product
infect
establish
multipl
critic
contact
membran
receptor
requir
infect
inhibit
steric
hindranc
geometr
constraint
see
also
parren
et
al
size
antibodi
molecul
second
antibodi
bind
well
coat
virion
surfac
neutral
viru
almost
univers
found
nonneutr
antibodi
coat
viru
although
may
bind
lower
level
occup
heterogen
envelop
spike
provid
opportun
bind
virion
without
neutral
low
occup
discuss
rabi
viru
fpvvsv
mix
virion
third
model
predict
precis
epitop
recogn
antibodi
virion
surfac
crucial
rather
number
antibodi
molecul
bound
per
unit
area
determin
affin
antibodi
virionexpress
antigen
import
precis
found
discuss
antibodi
enhanc
viral
infect
vitro
receiv
much
attent
although
signific
vivo
demonstr
dengu
viru
infect
appear
occur
presenc
subneutr
concentr
neutral
antibodi
model
describ
suggest
phenomenon
aris
low
occup
virion
site
discuss
earlier
question
whether
antibodi
bind
well
viru
without
neutral
often
rais
particular
concern
express
nonneutr
antibodi
might
compet
bind
neutral
antibodi
viru
therebi
interf
neutral
first
strongli
question
evid
bind
nonneutr
antibodi
gener
strong
correl
occup
neutral
exampl
nonneutr
antibodi
inde
explain
poor
viru
bind
even
failur
appreci
antibodi
bind
well
isol
envelop
capsid
molecul
necessarili
bind
well
viru
particl
convinc
isol
exampl
exist
rabi
mutant
viru
merit
investig
second
knowledg
convinc
confirm
evid
nonneutr
antibodi
interf
neutral
virion
coat
nonneutr
antibodi
therefor
appear
play
signific
role
humor
respons
virus
antibodi
activ
vivo
aris
bind
virion
virion
product
infect
cell
protect
antibodi
level
steril
immun
requir
activ
free
virion
ie
neutral
antibodi
sever
studi
mab
show
steril
immun
achiev
serum
concentr
challeng
anim
order
two
three
order
magnitud
higher
vitro
neutral
titer
serum
concentr
capabl
neutral
essenti
challeng
viru
express
anoth
way
serum
neutral
titer
requir
steril
protect
number
case
discuss
even
high
level
neutral
antibodi
provid
steril
protect
although
prevent
diseas
vaccin
elicit
high
neutral
titer
especi
extend
period
probabl
provid
steril
protect
rather
seem
immunolog
textur
antivir
activ
antibodi
like
reduc
effect
challeng
level
infect
cell
control
cellular
immun
possibl
antibodi
number
case
discuss
vivo
protect
neutral
antibodi
independ
presenc
fc
part
molecul
case
seem
like
mechan
protect
vivo
essenti
equival
neutral
vitro
number
case
appear
f
ab
fragment
equal
activ
whole
igg
molecul
neutral
vitro
ineffect
protect
neutral
mous
switch
variant
ineffect
protect
wherea
molecul
effect
mani
exampl
protect
independ
complement
suggest
protect
neutral
antibodi
requir
activ
infect
cell
well
free
virion
requir
case
activ
infect
cell
well
virion
may
contribut
observ
incomplet
correl
neutral
protect
neutral
antibodi
although
factor
use
differ
cell
type
vitro
vivo
consid
worth
emphas
though
neutral
antibodi
protect
appropri
concentr
antibodi
assess
potent
neutral
assay
vitro
gener
effect
protect
vivo
numer
exampl
protect
activ
exhibit
nonneutr
antibodi
activ
appear
direct
infect
cell
gener
appear
somewhat
less
potent
neutral
antibodi
instanc
case
describ
neutral
antibodi
protect
higher
challeng
dose
pathogen
virus
nonneutr
antibodi
mani
case
protect
nonneutr
antibodi
shown
depend
critic
fc
part
antibodi
molecul
occur
complementdefici
mice
suggest
adcc
phagocytosi
may
crucial
clear
antibodycomplex
infect
cell
note
protect
nonneutr
antibodi
mostli
restrict
protect
envelop
virus
signific
conclus
vaccin
design
first
case
timehonor
focu
elicit
neutral
antibodi
well
justifi
serum
neutral
antibodi
titer
order
greater
provid
greatest
likelihood
antibodi
alon
protect
viral
challeng
mani
case
antibodi
cellular
respons
may
cooper
protect
although
notabl
except
dittmer
et
al
underexplor
area
model
describ
assert
neutral
determin
extent
coat
viru
antibodi
given
antibodi
concentr
turn
determin
affin
antibodi
antigen
virion
surfac
henc
model
predict
vaccin
simpli
aim
elicit
antibodi
highest
affin
virion
surfac
antigen
directli
achiev
immun
molecul
ident
similar
viral
surfac
immunolog
textur
parren
burton
antigen
possibl
may
easi
argu
number
envelop
virus
evolv
surfac
protein
low
immunogen
subunit
envelop
protein
appear
number
instanc
elicit
antibodi
respons
show
littl
reactiv
form
envelop
usual
oligomer
express
virion
surfac
parren
et
al
roben
et
al
sakurai
et
al
sattentau
moor
anoth
interest
question
valu
elicit
antibodi
target
infect
cell
rather
virion
exampl
arenavirus
complet
passiv
protect
appear
requir
antibodi
infect
cell
well
virion
cours
neutral
antibodi
could
fulfil
role
bind
instanc
envelop
molecul
virion
infect
cell
howev
also
possibl
epitop
express
virion
express
optim
infect
cell
adcc
exampl
induct
nonneutr
antibodi
may
benefici
factor
worthi
consider
vaccin
design
particularli
use
subunit
protein
elicit
antibodi
final
could
passiv
administ
antibodi
use
treatment
acut
viral
diseas
studi
discuss
suggest
high
dose
would
requir
reason
chanc
efficaci
howev
given
avail
human
antibodi
new
technolog
transgen
mice
phage
display
green
et
al
lonberg
et
al
winter
et
al
abil
produc
larg
amount
antibodi
rel
cheapli
cultur
system
eg
verma
et
al
larger
anim
eg
pollock
et
al
plant
eg
fischer
et
al
antibodi
intervent
acut
viral
diseas
may
becom
increasingli
realist
antibodi
alreadi
use
certain
situat
postexposur
mode
prevent
eg
diseas
due
junin
viru
argentin
hemorrhag
fever
rabi
viru
tbev
howev
evalu
antibodi
human
follow
appear
symptom
infect
due
virus
rsv
dengu
hanta
would
great
interest
